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ABSTRACT 
Background: Nitazoxanide (Alinia
®
, NTZ) and its active circulating metabolite 
tizoxanide (TIZ) belong to a new class of anti-infective agents active against 
parasites, anaerobic bacteria, and viruses. Nowadays, NTZ is licensed in the 
United States for the treatment of diarrhea caused by Cryptosporidium parvum and 
Giardia lamblia in adults and children older than twelve months of age. The 
amplitude of the spectrum of pathogens targeted by NTZ and new-generation non-
nitro thiazolides, makes it very unlikely that the action of these compounds is 
mediated by a pathogen-specific mechanism(s), suggesting instead that thiazolides 
act as immunomodulants. To date, the potential effect of these compounds on 
immune responses has nevertheless not been analysed. In particular, because 
innate immunity and type 1 interferons are pivotal in early and effective antiviral 
immune responses that are not antigen-restricted, it is plausible to hypothesize that 
thiazolides could potentiate this arm of the immune system. To verify this 
possibility, we performed extensive in vitro analyses on the immunomodulatory 
effects of TIZ and the second generation non-nitro thiazolide RM4848 using two 
different models of viral infection: Influenza and HIV-1.  
Methods: Peripheral blood mononuclear cells (PBMCs) from 20 healthy donors 
were stimulated with influenza virus antigen (FLU) or infected with HIV-1BaL strain 
and cultured in presence/absence of TIZ or RM4848. Thiazolide effects on innate 
immunity were examined by evaluating TLRs expression on monocytes, IFN-
secretion by dendritic cells, cytokine and chemokine production, mRNA expression 
of multiple genes involved in TLR, type I IFN and in cholesterol metabolism 
pathways.  
Results: Thiazolides are associated with strong immunomodulatory effects. 
Notably, these compounds, both in FLU-stimulated and in HIV-1-infected cells, 
significantly increase: 1) TLR-expression on monocytes, 2) IFN production, 3) 
chemokine and cytokine production, 4) mRNA expression of different genes 
operating in the TLR and type I IFN pathways, 5) genes involved in cholesterol 
metabolism and efflux.  
Conclusions: Data herein show that thiazolides are potent type I IFN inducers, 
triggering a selective activation of several IFN-stimulated gene (ISG) pathway. 
Thus, increased expression of innate antiviral factors and the different modulation 
of genes involved in cholesterol metabolism and efflux suggest a new mechanism 
of action mediated by thiazolides.  
SOMMARIO 
Introduzione: La nitazoxanide (Alinia®, NTZ) ed il suo metabolita circolante attivo 
tizoxanide (TIZ), appartengono ad una nuova classe di farmaci dotati di 
comprovata attività contro parassiti, batteri anaerobi e virus. Ad oggi, la NTZ è 
approvata negli Stati Uniti per il trattamento di infezioni causate da 
Cryptosporidium parvum e Giardia lamblia nei bambini di età superiore ai 12 mesi 
e negli adulti. L’ampio spettro di patogeni verso cui questi farmaci risultano efficaci, 
lascia presupporre che il loro meccanismo d’azione non sia patogeno-specifico ma 
che agiscano attraverso la modulazione del sistema immunitario. Tuttavia, i 
potenziali effetti mediati da questi composti a livello della risposta immunitaria 
devono ancora essere chiariti. In particolare, vista l’importanza dell’immunità innata 
e degli Interferoni di tipo I nella risposta antivirale antigene-non specifica, è 
plausibile ipotizzare che i tiazolidi agiscano potenziando questo ramo del sistema 
immune. Per verificare questa ipotesi, abbiamo effettuato un'approfondita analisi in 
vitro degli effetti immunomodulanti esercitati dalla TIZ e dal RM4848, composto 
antivirale di seconda generazione, usando due differenti modelli di infezione virale: 
Influenza e HIV-1. 
Metodi: Cellule mononucleate isolate dal sangue periferico (PBMCs) di 20 donatori 
sani sono state stimolate con antigeni di influenza virus o infettate con HIV-1BaL in 
presenza o in assenza di TIZ o RM4848. Gli effetti esercitati dai tiazolidi 
sull’induzione dell’immunità innata sono stati valutati attraverso la quantificazione 
proteica dei TLR nei monociti, di IFN in cellule dendritiche plasmacitoidi e la 
produzione di citochine e chemochine. Infine, è stata valutata, utilizzando Real 
Time PCR array, l’espressione di geni coinvolti nel pathway dei TLR, degli IFN e 
del metabolismo del colesterolo intracellulare.  
Risultati: Complessivamente i tiazolidi mostrano un potente effetto 
immunomodulante. In particolare, tali composti, aumentano significativamente: 1) 
l’espressione dei TLR nei monociti, 2) la produzione di IFN, 3) la produzione di 
chemochine e citochine, 4) l’espressione di diversi geni coinvolti nel pathway dei 
TLR e in quello degli IFN, 5) l’espressione di geni coinvolti nel metabolismo del 
colesterolo. 
Conclusioni: I risultati ottenuti dimostrano che i tiazolidi sono potenti induttori degli 
IFN di tipo I e innescano una selettiva attivazione di diversi geni IFN-dipendenti. 
Pertanto, l’aumentata espressione di fattori antivirali appartenenti all’immunità 
innata e la diversa modulazione di geni coinvolti nel metabolismo e nell’efflusso del 
colesterolo intracellulare suggeriscono un meccanismo d’azione del tutto nuovo 
mediato dai tiazolidi. 
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1. THIAZOLIDES 
1.1. History 
The discovery of thiazolides finds its origin in the mid-1970s [1]. During that period, 
nitroimidazoles were developed for treatment of parasitic diseases, including 
trichomoniasis, giardias and amebiasis, with metronidazole as the main compound 
[2]. Afterwards, benzimidazole carbamate derivatives, as mebendazole and 
albendazole, profoundly improved the treatment of intestinal parasitic infection 
caused by nematodes [3]. The discovery and development of praziquantel 
provided the first broad spectrum anthelminthic compound, effective against 
schistosomes and intestinal cestode infections [4].  
In developing countries, the need for antiparasitic drugs with broad spectrum 
activity against protozoa and helminthes arose from the difficult diagnose due to 
the simultaneous infection with several intestinal pathogens. A product provided 
with this multi-functional characteristics did not exist. Albendazole was eventually 
discovered to be effective in treating giardiasis, but not until the mid-1980s [5]. 
Thus, Rossignol et all. of the Romark Institute for Medical Research (Tampa, 
Florida) used the scaffold niclosamide, a commercially available cestocidal 
anthelminthic, to design nitazoxanide (NTZ), originally known as PH5776 (fig. 1) 
[1].  
 
Figure 1 NTZ structure [Rossignol J.F., United States patent 1976] 
 
A nitrothiazole ring was selected to resemble a nitroimidazole derivative with the 
expectation to be effective against protozoa whereas the salicylate portion of the 
molecule was left unchanged [1].  
Extensive in vitro tests of NTZ, confirmed its efficacy against nine different 
intestinal parasites of mice, cats, dogs and sheep [6]. Moreover, NTZ was found to 
be effective in vitro and in animal models against Trichomonas vaginalis and 
Entamoeba histolyca [7]. Development of NTZ was set aside in the early 1980s, 
and over the next 10 years antiparasitic drug development focused on 
albendazole, a single dose anthelmintic with exceptional activity against intestinal 
nematodes and some cestodes [8]. In the attempt to address the emergence of 
new opportunistic protozoan infection in AIDS (Acquired Immunodeficiency 
Syndrome) patients, mainly Cryptosporidium parvum, the development of NTZ 
started again in early 1990s. After demonstrating its efficacy against C. parvum in 
cell cultures and in several animal models [9], NTZ received regulatory approval in 
the US in 2002 for treatment of Criptosporidium parvum and Giardia intestinalis 
infections in non-immunodeficient children and adults [10].  
In vitro analysis for antiviral activity led to the discovery of NTZ’s efficacy against a 
wide range of DNA and RNA virus including Hepatitis B Virus (HBV) and Hepatitis 
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C Virus (HVC) [11-12]. Results from clinical studies concerning the role of NTZ in 
viral infections treatment motivated the search for new compounds with exclusive 
activity against viruses. Extensive studies about the mechanism of action of this 
compound identified the nitro group as responsible for the anti-protozoa and –
bacteria properties [13]. Thus, the substitution of the nitro group in the 5-position of 
the thiazole ring by an electrophilic non-reducible function led to the synthesis of 
second-generation thiazolides with higher efficacy against viruses [14-15]. To date, 
NTZ and new compounds are extensively tested in human clinical trials for the 
treatment of different pathological conditions. 
1.2. Pharmacology of thiazolides 
NTZ is a synthetic nitrothiazolyl-salicylamide derivative. Chemically it is 2-
acetyloxyl-N-(5-nitro-2 thiazolyl) benzamide, composed of a nitrothiazole-ring and a 
salicylic acid moiety which are linked together by an amide bond. Derivatives of 
NTZ are those in which the acyloxy group, represented in tab.1 by the R1, R2, R3, 
R4 and R5 symbols, is an acetoxy or propionoxy group, whereas the alkaloxy group 
is the methoxy group and the halogen is chlorine or bromine [15].  
 
Table 1 – Chemical structures of NTZ and some halogeno thiazolide agents 
 
Thus, the elimination of the nitro group in second generation thiazolides resulted in 
a significant advance for this class of drugs, given its poor reputation from a 
toxicological perspective.  
NTZ, commercialized with the brand name Alinia® (Romarck Laboratories) is 
formulated as 500 mg tablets and as a 100 mg per 5ml suspension for oral 
administration (fig. 2). The recommended dosage is: 100 mg (by oral suspension) 
every 12 hours for 3 days for children aged 1 to 3 years; 200 mg (by oral 
suspension) every 12 hours for 3 days, for children aged 4 to 11 years; 500 mg 
(oral suspension or oral tablets) every 12 hours for 3 days, for children older than 
12 years or adults [16].  
Clinical pharmacology studies showed that NTZ was actually well absorbed in 
humans [17-19]. A study conducted in six human volunteers receiving a single 500 
mg p.o. dose of 
14
C-labeled NTZ in capsules in fasted conditions showed that 33% 
of the drug was excreted in urine whereas the rest was excreted with feces over a 
period of 240 h [18]. Notably, it was demonstrated that the administration of NTZ 
tablets with food increases the oral absorption by 50% [18].  
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Figure 2 – Alinia® Romark Lab. (Tampa, Florida) 
 
Moreover, NTZ revealed good metabolic stability. The drug undergoes rapid 
deacetylation in plasma (half-life of 6 minutes) to form tizoxanide (TIZ), which is at 
least as active as NTZ against anaerobes and viruses [17-19]. TIZ is glucurono-
conjugated in the liver, and the drug is excreted as TIZ or TIZ-glucuronide in urine 
and bile. TIZ-glucuronide albeit it is essentially an excretion metabolite, retains 
some moderate antimicrobial properties of the parental compound [18]. Plasma 
concentration of TIZ and TIZ-glucuronide achieves maximum between 1 to 4 hours 
following ingestion [17-19]. Active metabolites are essentially completely protein 
bound (>99%), whereby caution should be used when administering NTZ 
simultaneously with other highly plasma protein-bound drugs, as competition for 
binding sites may occur (e.g., warfarin) [17-19]. In vitro metabolic studies have 
demonstrated that TIZ has no significant inhibitory effect on cytochrome P450 
enzymes [19-20]. Thus, it is expected that no significant interaction would occur 
when NTZ is administered with drugs that are metabolized by or inhibit this 
enzymes. NTZ is generally well tolerated, and no significant adverse events have 
been recorded in human trials. Side effects are mild and transitory and principally 
related to the gastrointestinal tract, such as abdominal pain, diarrhea, and nausea. 
In addition, no significant changes have been reported in relation to 
electrocardiography, vital signs, or hematologic, clinical chemistry, or urinalysis 
parameters in patients treated with NTZ [20].  
In subacute and chronic toxicity studies, NTZ showed no toxicity in rats when 
administered at doses < 450 mg/kg/day for 6 months, 30 times the proposed 
human dose [20-21]. In a 28-day subacute toxicity study, doses of < 2700 
mg/kg/day p.o. determined significant and limiting toxicity for the gastrointestinal 
tract. Interestingly, these dose levels did not produce systemic toxicity [20-21]. 
Subsequently, a 9-month chronic study showed that administration of 60 
mg/kg/day, 4 times the proposed human dose, did not produce toxicity in dogs 
[Romarck Laboratories, pers. commun.]. No embryotoxic or teratogenic effects 
resulted from studies in different animal models, and the drug received approval in 
the US with a pregnancy category B classification [21].  
NTZ and TIZ showed weak positive results in the Ames test using TA100 strain of 
Salmonella typhimurium, but neither NTZ nor TIZ were found to be mutagenic [21].  
New generation thiazolides show a very similar metabolic profile. These drugs are 
rapidly hydrolyzed in plasma to form their active de-acetylated metabolites.  
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Like NTZ and TIZ, second generation thiazolides family members are highly bound 
to plasma proteins and do not interact with the important CYP enzymes, 
suggesting a low potential for drug interaction (Romark Lab, pers. Commun.). 
Preliminary subacute toxicity studies in rats and dogs with the second generation 
thiazolide RM4865, have shown very little systemic toxicity and better tolerability in 
dogs than that observed with NTZ. As with other thiazolides, RM4865 is also not 
mutagenic in the Ames test (Romarck Laboratories, pers. Commun.). 
1.3. In vitro activity  
1.3.1. Protozoa and anaerobic bacteria  
In humans, NTZ has been reported to be effective against a broad range of 
parasites, including Giardia lamblia, Entamoeba histolytica, Cryptosporidium 
parvum, Cyclospora cayetanensis, Trichomonas vaginalis, Vittaforma corneae, 
Encephalitozoon intestinalis, Isospora belli, Blastocystis hominis, Balantidium coli, 
Enterocytozoon bieneusi, Ascaris lumbricoides, Trichuris trichura, Taenia saginata, 
Hymenolepis nana, and Fasciola hepatica [2,7,9,10,22-32]. In vitro studies have 
also shown antimicrobial activity against numerous gram-positive and gram-
negative anaerobic bacteria and against aerobic gram-positive bacteria [33-34].  
Studies of protozoa and anaerobic bacteria have shown that NTZ interferes with 
pyruvate-ferrodoxin oxidoreductase (PFOR) enzyme dependent electron transfer 
reaction which is important for anaerobic glucose energy metabolism [13-14]. This 
results in cell swelling, membrane damage and vacuole injury and in the 
consequently dysfunction of the parasite. As this activity depends on the nitro 
group, second generation thiazolides might not be effective against anaerobic 
bacteria and protozoa that affects human [14]. Nevertheless, inhibition of PFOR 
enzyme might not be the only pathway by which NTZ exhibits antiprotozoal activity, 
and the mechanism of NTZ’s activity against helminthes is still unknown.  
In vitro studies have shown NTZ ability to inhibit the growth of sporozoites of C. 
Parvum on its own, and have also established a combined in vitro activity with both 
azithromycin and rifampin, against C. Parvum by 83.9% and 79.8%, respectively, 
compared with 56.1% when used alone [26]. Similarly, in vitro studies of NTZ and 
TIZ, revealed greater efficacy than metronidazole against G. intestinalis [26]. The 
antimicrobial properties of NTZ and TIZ have been verified against 241 anaerobes, 
the majority of which were inhibited in vitro, with an MIC90 between 0.06 mg/L and 
4 mg/L [33]. NTZ has also shown in vitro and in vivo antimicrobial activity against 
Clostridium difficile [32] and both metronidazole-susceptible and metronidazole-
resistant strains of H. pylori [34,35]. 
1.3.2. Virus 
NTZ, TIZ and new generation thiazolides have been shown to inhibit replication of 
rotavirus, HBV and HCV in a selective and dose-dependent manner [11,12]. 
Thiazolides have also been reported to be active against influenza A virus, Sendai 
virus, respiratory syncytial virus, coronavirus, vescicular stomatitis virus, 
adenovirus and herpes simplex virus type I [36,37]. 
The antiviral activity of the thiazolides is distinct from the one against anaerobic 
protozoa and bacteria that has been related to interference with PFOR enzyme. 
Although the mechanism remains to be clarified, these drugs showed interesting 
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characteristics in laboratory studies that indicate a novel device that could be 
complementary to other antiviral drugs.  
Studies in rotavirus have shown that NTZ is cytoprotective [38]. Studies in HBV 
have demonstrated that NTZ inhibits production of the HBV surface antigens [11]. 
NTZ is also synergistic with lamivudine and adefovir against HBV, and it is active 
against lamivudine- and adefovir-resistant isolates of HBV [11]. Studies in HCV 
replicons have shown that NTZ is synergistic with interferon alpha, telaprevir (a 
protease inhibitor) and 2’C-methyl cytidine (a polymerase inhibitor) and that it is 
active against telaprevir- and 2’C-methyl cytidine-resistant mutants [11,39]. 
Interestingly, HCV replicons exposed to NTZ and subsequently treated with 
interferon show significantly greater sensitivity to the interferon antiviral effects [11, 
40]. Studies in HCV replicons have shown that NTZ does not induce viral mutations 
that could promote resistance development [40]. Efforts to select HCV replicons 
resistant to NTZ resulted in a significant increase in cytotoxic concentrations 
suggesting a mechanism of action that is host cell-mediated [40].  
Finally, NTZ induces phosphorylation of eukaryotic initiation factor-2(eIF2) via 
activation of the protein kinase activated by double-stranded RNA (PKR), a critical 
IFN-induced antiviral response mediators [41]. 
Teams of researchers are studying the mechanism of antiviral activity of 
thiazolides. Preliminary findings about the potent anti-influenza A activity exerted 
by thiazolides suggest that they act a post-translational level by selectively blocking 
hemagglutinin (HA) maturation, without directly affecting virus infectivity [37]. It was 
demonstrated that TIZ impairs HA trafficking between the ER and the Golgi 
complex, preventing its transport and insertion into the host cell plasma membrane 
and blocking the exit of mature virions [37]. Targeting the maturation of the viral HA 
offers the opportunity to interfere with viral particle production acting at a different 
level from the currently available anti-influenza drugs.  
1.3.3. Cancer  
Although NTZ was originally designed as an anti-microbial drug, anti-cancer 
properties have also been observed. It has been established that NTZ and/or 
bromo-thiazolide RM4819 treatment inhibits colon cancer cells proliferation in vitro, 
by binding to glutathione S-transferase P1 protein (GSTP1) [42]. GSTP1 protein 
expression has been recently correlated to tumor tissue and ovarian cancer 
prognosis [43]. In particular high levels of GSTP1 in tumor cells may greatly limit 
the efficacy of antitumor chemotherapy [43].  
Furthermore, NTZ has shown also anti-Myc activity [44].The c-Myc oncogene is 
overexpressed and amplified in the majority of human cancers and and it is 
inversely correlated with prognosis. c-Myc controls cell proliferation and is critically 
involved in the regulation of many growth-promoting signal transduction pathways 
[44]. In particular, it is established its role in complex inflammatory responses 
leading to the recruitment of various inflammatory cells with pro-tumorigenic 
behavior. In breast cancer xenograft mouse models, NTZ significantly suppressed 
tumor growth by inhibiting c-Myc and inducing apoptosis [44]. These findings 
support NTZ’s potential as a new, anti-tumor agent for the inhibition of c-Myc 
associated neoplasia. 
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1.4. NTZ for the treatment of viral infections: human experience 
[Romark Lab. personal communications]  
The safety and tolerability of NTZ in humans has been documented by >10 years 
of its commercial use. More than 20 million people have been treated with NTZ in 
post-marketing experience, most of them for relatively short durations ranging from 
3 to 10 days. In clinical trials > 700 patients have received much longer treatments 
without significant drug-related side effects. 
Figure 3 – Clinical trial phases 
 
1.4.1. Completed Studies 
1.4.1.1. Hepatitis C Virus infection treatment: STEALT C Clinical Development 
Program and OPTIMA HCN program  
The first Phase II randomized, controlled trial is included in the STEALTH C 
(Studies to Evaluate Alinia for Treatment of Hepatitis C) clinical development 
program, designed to estimate the safety and efficacy of NTZ tablets in 
combination with peg-interferon or peg-interferon and ribavirin (standard of care, 
SOC) in HCV patients. In this trial, conducted at two centers in Egypt, 96 
treatment-naive patients with HCV genotype 4 were randomly assigned into three 
groups to receive either 48 weeks of SOC treatment (n=40), 12 weeks of NTZ 
followed by 36 weeks of NTZ plus peginterferon (a dual regimen, n=28), or 12 
weeks of NTZ followed by 36 weeks of NTZ plus SOC treatment (a triple regimen, 
n=28). An additional 24 patients previously interferon-treated were randomized to 
receive 12 weeks of NTZ followed by either the dual regimen (n=12) or the triple 
regimen (n=12) for 36 weeks.  
Naïve patients receiving the triple regimen showed a significantly higher sustained 
virological response (SVR: HCV RNA < 10 IU/mL, Abbott m2000) than the group 
receiving the SOC regimen (79% vs. 43%, respectively) (p=0.006) 12 weeks after 
the end of the treatment. At the same time, patients treated with the dual regimen 
showed a SVR not inferior to SOC (68% vs. 43%, respectively) (+25%; 95% CI: -
1%, +47%). Of 24 treatment-experienced patients, the triple regimen (n=12) 
resulted in an SVR of 25% at week 12 post-treatment, and the dual regimen group 
(n=12) had an SVR of 8%. 
STEALTH C1
2
 phase II trial was) was planned to evaluate the possibility to reduce 
the lead-in phase from 12 to 4 weeks. Therefore, 44 patients (40 with HCV 
Up to several 
months 
Up to 2 years 1-4 years 
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genotype 4; 3 with HCV genotype 1; and 1 with HCV genotype 2) received 4 weeks 
of NTZ 500 mg twice daily followed by Pegasys® (peginterferon alfa-2a) and NTZ 
for 36 weeks. STEALTH C1 trial was used as an historical control. The 80% (44) of 
patients treated with a 4-week lead-in phase of NTZ followed by the addition of 
peginterferon for 36 weeks reached a SVR 12 weeks after the end of treatment 
compared to 50% in the SOC historical control group (P=0.004), 61% in patients 
receiving a 12-week lead-in with NTZ followed by 36 weeks of NTZ plus 
peginterferon, and 79% in patients receiving a 12-week lead-in with NTZ followed 
by 36 weeks of NTZ plus SOC. Of the 44 patients in the study, 78% (n=40) of 
patients with HCV genotype 4, 100% (n=3) of patients with HCV genotype 1, and 
100% (n=1) of HCV genotype 2, had undetectable virus at 12 weeks after the end 
of treatment. 
STEALTH C2 double-blind, placebo controlled trial  enrolled US patients with 
genotype 1 chronic hepatitis C who had previously failed to respond (never 
achieved undetectable HCV RNA) to peginterferon plus ribavirin. 64 patients were 
randomized 2:1 to receive NTZ 500 mg twice daily for 4 weeks followed by 48 
weeks of NTZ plus standard therapy (Pegasys® and Copegus®, F. Hoffman 
LaRoche) or placebo for 4 weeks followed by 48 weeks of placebo plus standard 
therapy. The 7% (3/42) of patients treated with NTZ plus standard therapy reached 
SVR 24 week following the end of treatment compared to 0% (0/22) of patients 
treated with placebo plus standard therapy. 
Results from others endpoints concerning rapid virological response (RVR), 
complete early virologic response (cEVR), early virological response (EVR) and 
end of treatment response (ETR) are shown in Tab. 2. No serious adverse event 
has been related to NTZ.  
 
 
Table 2 – STEALTH-C2 study: results [Romark pers. comm.] 
 
The last of this series of clinical trials is the randomized double-blind placebo 
controlled trial STEALTH C3. This  randomized, double-blind, placebo controlled 
trial enrolled patients with genotype 1 chronic hepatitis C, 35% of whom had 
advanced stage 3 or 4 fibrosis from thirteen centers in the United States 112 
patients were randomized to receive either NTZ (500 mg twice daily) plus 
peginterferon alfa-2a (Pegasys®, F. Hoffman LaRoche) and ribavirin (Copegus®, 
F. Hoffman LaRoche) (n=75) or placebo plus Pegasys® and Copegus® (n=37). 
SVR 24 week after the end of the treatment occurred in 44% of patients treated 
with NTZ plus standard therapy for 48 weeks versus 32% of patients treated with 
placebo plus standard therapy.  
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In patients with high baseline viral load 41% vs. 29%) and in African Americans 
(38% vs. 20%), SVR rates were consistently higher. Moreover, the rate of serious 
adverse event were similar for the NTZ and placebo treatment groups.  
Subsequently, Romark Lab., performed two different trials, as part of Romark’s 
OPTIMA HCN (OPTImizing Management of Hepatitis C with NTZ) program. 
OPTIMA HCN-1, a ramdomized, double blind crossover phase 1 study enrolled a 
total of 12 healthy adults volunteers in order to study pharmacokinetic following oral 
administration of  675 mg or 1350 mg of NTZ twice daily with food for seven days. 
This two different doses of controlled release NTZ produced 3x and 12x plasma 
concentrations of TIZ compared to that  observed in historical studies using a 
standard NTZ 500 mg tablet. Controlled release NTZ showed favorable safety and 
tolerability during the course of the study, with slight to moderate adverse events 
reported.  
Phase II study, OPTIMA HCN-2, a total of 41 treatment-naïve patients with chronic 
hepatitis C genotype 4 were randomized to receive NTZ at 675 mg (n=17), NTZ at 
1350 mg (n=16) or placebo (n=8) twice daily for four weeks followed by the same 
regimen plus SOC with peginterferon alfa-2a (Pegasys®; 180 micrograms once per 
week) and ribavirin (Copegus®; 1,000 or 1,200 mg daily according to body weight) 
for 36 weeks (48 weeks for the placebo arm). 59% and 63% of patients treated with 
the low and the high dose of NTZ showed RVR (HCV RNA <12 IU/mL after 4 
weeks of combination therapy), compare with 50% for the placebo group; 82% and 
100%, respectively, showed cEVR (HCV RNA <12 IU/mL after 12 weeks of 
combination therapy) compared with 63% for the placebo group; 88% and 100%, 
respectively, showed early virologic response (EVR, =2 log10 decline in HCV RNA 
after 12 weeks of combination therapy) with 63% for the placebo.  
Moreover, a dose-related decrease in serum HCV RNA was observed starting on 
day 4 of combination therapy and was maintained till week 16. No serious adverse 
events have been reported following NTZ treatment.  
1.4.1.2. Influenza Virus treatment: clinical trial  
Two Phase 2 clinical trials, one in pediatric patients age 1 to 11 years, and another 
in adults and adolescents age 12 – 65 years, were conducted in Cajamarca, Peru. 
Patients were enrolled based upon influenza symptoms (fever, at least one 
respiratory symptom and one constitutional symptom) and randomized to receive 
treatment with NTZ or placebo in double-blind manner.  
One hundred children (median age 3 years) enrolled in the pediatric trial (50 per 
treatment group), received 100 mg NTZ (age 12 – 47 months), 200 mg NTZ (age 
4–11 years) or placebo twice daily for five days as an oral suspension.  
Heighty-six adults and adolescents enrolled in the second trial (43 per treatment 
group)received 500 mg NTZ or placebo twice daily for five days as an oral tablet.  
A statistically significant reduction in symptom duration has been obtained following 
treatment with NTZ compared to placebo, in both trials. In the pediatric study, 
median time from first dose to alleviation of symptoms was 4 days for the NTZ 
treatment group compared to >7 days for the placebo treatment group (P<0.0001). 
In the study involving adults and adolescents, median time from first dose to 
alleviation of symptoms was 4 days compared to 7 days for the placebo treatment 
group (P=0.037). In the pediatric study, 60% of the patients in the placebo 
treatment group required post-study antibiotics compared to only 8% in the NTZ 
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treatment group (P<0.0001). In the adult/adolescent study, 36% of the patients in 
the placebo treatment group required post-study antibiotics compared to 18% in 
the NTZ treatment group (P=0.13). In each study, adverse events were similar 
between the treatment groups. 
1.4.2. Ongoing studies 
A global Phase 3 clinical trial of NTZ-300 for the treatment of acute 
uncomplicatedhas been started in April 2013 in the United Stated, in order to 
provide data for marketing approval. This study will extend in Australia and New 
Zealand and is expected to be completed during the 2013-2014 FLU season in the 
northern hemisphere. Moreover, the aim is also to combine treatment with NT-300 
and oseltamivir in an effort to improve treatment and to mitigate the risk of 
oseltamivir resistance.  
The clinical trial will enroll a total of 1400 patients with fever and other symptoms of 
influenza. Patients are being randomized to receive treatment with either NT-300, 
placebo (sugar pill), oseltamivir (Tamiflu
®
) or NT-300 plus oseltamivir. The primary 
objectives of the study are to evaluate the reduction of symptoms duration. 
Currently, there are only two classes of drugs approved in the United States for 
treating influenza, and only the neuraminidase inhibitors, oral Tamiflu
®
 (oseltamivir) 
and inhaled Relenza
®
 (zanamivir), are recommended for use. New drugs with 
different mechanisms of action could be important in overcoming drug resistance 
and providing better treatment for patients with influenza. The Phase 3 clinical trial 
of NT-300 will be fully funded by the U.S. Department of Health and Human 
Services (HHS)/Office of the Assistant Secretary of Preparedness and Response 
(ASPR)/Biomedical Advanced Research and Development Authority (BARDA).  
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2. VIRAL INFECTIONS 
2.1. Influenza (FLU) virus 
Influenza viruses are among the most common causes of human respiratory 
infections [45] with an high morbidity and mortality. Up to 50% of the population 
can be infected in a single pandemic year, and the number of deaths caused by 
influenza can dramatically exceed what is normally expected [46].  
Influenza viruses, of the family Orthomyxoviridae, are enveloped negative-strand 
RNA viruses with segmented genomes containing seven to eight gene segments 
[47] (fig. 4).  
 
 
 
 
Figure 4 - The structure of influenza A virus [Nelson M.I., Nat Rev Gen, 2007] 
 
One genus includes influenza A and B viruses, and the other comprises influenza 
C viruses. The three virus types differ in host range and pathogenicity. Type B and 
C influenza viruses are isolated almost exclusively from humans, although 
influenza B viruses have been isolated from seals and influenza C viruses have 
been isolated from pigs and dogs. 
Influenza A and B viruses have a similar structure, whereas influenza C is more 
divergent. The virus particle is 80–12 nm in diameter and usually roughly spherical, 
although filamentous forms can occur. These filamentous forms are more common 
in influenza C, which can form cordlike structures up to 500 micrometres long on 
the surfaces of infected cells.  
A and B type viruses contain eight discrete gene segments, each of them coding 
for at least one protein, and are covered with projections of three proteins: 
hemagglutining (HA), neuraminidase (NA) and M2. For example, the influenza A 
genome contains 11 genes on eight pieces of RNA, encoding for 11 proteins: HA, 
NA, NP, M1, M2, NS1, NS2, PA, PB1, PB1-F2 and PB2. Influenza C viruses have 
seven segments and only one surface glycoprotein (fig.5).  
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Figure 5 - Genome organization of FLU viruses [Kumar V., Robbins Basic Pathology, 2007] 
 
HA and NA are the two large glycoproteins on the outside of the viral particles. HA 
is an integral membrane glycoprotein, constituted by three identical monomers 
constructed into a central α-helix coil; three spherical heads contain the sialic acid 
binding sites. HA monomers are synthesized as precursors (HA0) that are then 
cleaved into two smaller polypeptides: the HA1 and HA2 subunits. HA has two 
functions. Firstly, it allows the recognition of target cells, accomplished through the 
binding of these cells sialic acid-containing receptors. Secondly, once bound, it 
facilitates the entry of the viral genome into the target cells by causing the fusion of 
host endosomal membrane with the viral membrane [48].  
NA exists as a projection on the surface of the influenza virus. It has a head 
consisting of four subunits, and a hydrophobic region that is embedded within the 
interior of the virus membrane. NA catalyzes the hydrolysis of terminal sialic acid 
residues from the newly formed virions and from the host cell receptors. 
Viruses can only replicate in living cells. Influenza infection and replication is a 
multi-step process [49] (fig. 6). Influenza viruses bind through HA to sialic acid 
residues on the surface of its target cells. Upon binding, receptor-mediated 
endocytosis occurs and the virus enters the host cell in an endosome. The cell then 
attempts to begin digesting the contents of the endosome by acidifying its interior 
and transforming it into a lysosome. The low pH induces a conformational change 
in HA0, leading to maintenance of the HA1 receptor-binding domain but exposing 
the HA2 fusion peptide. This fusion peptide inserts itself into the endosomal 
membrane, bringing both the viral and endosomal membranes into contact with 
each other and causing the two to fuse together.  
Finally the M2 ion channel allows protons to move through the viral envelope and 
acidify the core of the virus, which causes the release of viral RNA, accessory 
proteins and RNA-dependent RNA polymerase into the cytoplasm. These proteins 
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and viral RNA are transported into the cell nucleus, where the RNA-dependent 
RNA polymerase begins transcribing complementary positive-sense viral RNA. 
Viral RNA is either exported into the cytoplasm, and translated, or remains in the 
nucleus. Newly synthesised viral proteins are either secreted onto the cell surface 
or transported back into the nucleus to bind viral RNA and form new viral genome 
particles. Negative-sense viral RNAs that form the genomes of future viruses, 
RNA-dependent RNA polymerase, and other viral proteins are assembled into a 
virion. 
 
 
 
 
Figure 6 – Influenza virus life-cycle [Neumann G., Nature, 2009] 
 
HA and NA molecules cluster into a bulge in the cell membrane. The viral RNA and 
viral core proteins leave the nucleus and enter this membrane protrusion. The 
mature virus buds off from the cell in a sphere of host phospholipid membrane, 
acquiring HA and NA with this membrane coat. NA promotes the release of 
progeny viruses and the spread of the virus from the host cell to uninfected 
surrounding cells. It also cleaves sialic acid residues from viral proteins, preventing 
aggregation of viruses (fig. 7). Thus, its activities include assistance in the mobility 
of virus particles through the respiratory tract mucus and in the elution of virion 
progeny from the infected cells. After the release of new influenza viruses, the host 
cell dies.  
Influenza viruses accumulate point mutations during replication because their RNA 
polymerase complex has no proofreading activity. Their genes have high mutation 
rates (ranging from approximately 1 × 10
3
 to 8 × 10
3
 substitutions per site per 
year). Mutations that change amino acids in the antigenic portions of surface 
glycoproteins may produce selective advantages for viral strains by allowing them 
to evade pre-existing immunity.  
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Figure 7 – Influenza virus neuraminidase activity [Moscona A., N Engl J Med, 2005] 
 
The HA molecule initiates infection by binding to receptors on specific host cells. 
Antibodies against the HA protein prevent receptor binding and are effective at 
preventing re-infection with the same strain. The HA and NA can evade previously 
acquired immunity by either antigenic drift, in which mutations limit or prevent 
antibody binding, or antigenic shift, in which the virus acquires HA of a new 
subtype by re-assortment between two influenza A viruses [50]. Antigenic drift 
occurs in all types of influenza including influenza virus A, influenza B and 
influenza C. Antigenic shift, however, occurs only in influenza virus A because it 
infects more than just humans. Affected species include other mammals and birds, 
giving influenza A the opportunity for a major reorganization of surface antigens. 
Influenza B and C principally infect humans, minimizing the chance that a re-
assortment will change its phenotype drastically. Although an antigenically novel 
HA subtype is a likely requirement for the emergence of an influenza pandemic, 
human infections with animal-adapted influenza virus of novel HA subtype have 
been observed in which the virus is not transmitted efficiently from person to 
person, suggesting that stable adaptation to humans by re-assortment or whole 
genome adaptation is required for the emergence of a pandemic strain.  
Influenza is an acute respiratory disease characterized in its full form by the 
sudden onset of high fever, nasal congestion, cough, headache, prostration, 
malaise and inflammation of the upper respiratory tree and trachea. In most cases, 
pneumonic involvement is not clinically prominent. Acute symptoms and fever often 
persist for 7 to 10 days. Weakness and fatigue may linger for weeks. 
People with chronic pulmonary or cardiac disease, or diabetes mellitus, are at high 
risk of developing severe complications from influenza A viruses, which may 
include hemorrhagic bronchitis, pneumonia (primary viral or secondary bacterial) 
and death. Fulminant fatal influenza viral pneumonia occasionally occurs; dyspnea, 
cyanosis, hemoptysis, pulmonary edema and death may proceed in as little as 48 
hours after the onset of symptoms.  
The mechanisms by which influenza infection causes symptoms in humans have 
been studied intensively. Knowing which genes are carried by a particular strain 
can help predict how well it will infect humans and how severe this infection will be 
[51] from influenza-infected cells. For instance, part of the process that allows 
influenza viruses to invade cells is the cleavage of the viral HA protein by any one 
of several human proteases. In mild and avirulent viruses, the HA can only be 
cleaved by proteases found in the throat and lungs, so these viruses cannot infect 
other tissues. However, in highly virulent strains, such as H5N1, the HA can be 
cleaved by a wide variety of proteases, allowing the virus to spread throughout the 
body. Strains that are easily transmitted between people have HA proteins that 
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bind to receptors in the upper part of the respiratory tract, such as in the nose, 
throat and mouth. In contrast, the highly lethal H5N1 strain binds to receptors that 
are mostly found deep in the lungs. This difference in the site of infection may be 
part of the reason why the H5N1 strain causes severe viral pneumonia in the lungs, 
but is not easily transmitted by people coughing and sneezing.  
Common symptoms of influenza such as fever, headaches, and fatigue are the 
result of the huge amounts of proinflammatory cytokines and chemokines (such as 
IFN-γ and TNF-α) produced from influenza-infected cells [52]. Influenza does 
cause tissue damage, so symptoms are due to either a massive immune response 
that produce a life-threatening cytokine storm or the massive levels of viral 
replication inside the infected cells.  
Effective measures against influenza A and B diseases include prevention of 
infection by either vaccination with inactivated or live attenuated vaccines or 
administration of antiviral drugs prophylactically or therapeutically. Chemically 
inactivated influenza vaccines consist of detergent-split virion subunits composed 
of HA and lesser amounts of other virion proteins including NA. This inactivated, 
split vaccine is not completely effective, particularly in the elderly. The efficacy of 
the vaccine is significantly compromised when circulating viruses do not have a 
good match with vaccine strains due to antigenic drift or inaccurate epidemiological 
predictions. A live, attenuated influenza virus vaccine (FluMist®) is also licensed 
for seasonal influenza and is intended for intranasal administration to people 6 
months to 49 years of age. Current influenza vaccines normally protect only for a 
matter of months; in any case, continuous viral antigenic drift of influenza A viruses 
makes once effective vaccines ineffective after few time. Furthermore, they do not 
generate broadly neutralizing antibodies to multiple strains of influenza and must 
be re-formulated annually to match the predominant virus strains circulating each 
year. Antiviral drugs can have both therapeutic and prophylactic effects, but to 
prevent disease they must be administered continuously at times of high influenza 
activity. Matrix 2 ion channel blockers are effective against influenza A viruses, but 
resistant viral strains develop rapidly and have been recognized in approximately 
one-third of treated patients. The more recently developed NA inhibitors are 
effective against both influenza A and B viruses. Both classes of drugs are effective 
in preventing influenza when administered prophylactically [53]. However, the 
importance of predicting the emergence of new circulating influenza strains for 
subsequent annual vaccine development cannot be underestimated. 
2.2. Human immunodeficiency virus (HIV) 
HIV remains one of the leading causes of mortality and morbidity worldwide. The 
virus infects 15.000 people every day and causes millions of death every years.  
HIV is a member of the family Lentiviridae. Two closely related types of HIV, 
designated HIV-1 and HIV-2, have been identified. HIV-1 is by far the most 
common cause of AIDS, but HIV-2, which differs in genomic structure and 
antigenicity, causes a similar clinical syndrome [54].  
An infectious HIV particle consists of two identical strands of RNA packaged within 
a core of viral proteins and surrounded by a phospholipid bilayer envelope derived 
from the host cell membrane but including virally encoded membrane proteins (fig. 
8). The RNA genome of HIV is approximately 9.2 kb long and has the basic 
arrangement of nucleic acid sequences characteristic of all known retroviruses. 
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LTRs at each end of the genome regulate viral gene expression, viral integration 
into the host genome, and viral replication. The gag sequences encode core 
structural proteins. The env sequences encode the envelope glycoproteins gp120 
and gp41, which are required for infection of cells. The pol sequences encode 
reverse transcriptase, integrase, and viral protease enzymes required for viral 
replication. In addition to these typical retrovirus genes, HIV-1 also includes six 
other regulatory genes, namely, the tat, rev, vif, nef, vpr, and vpu genes, whose 
products regulate viral reproduction in various ways. 
 
   
Figure 8 - HIV-1 virion [Kumar V., Robbins Basic Pathology, 2007] 
 
HIV infection of cells begins when the envelope glycoprotein (Env) of a viral particle 
binds to both CD4 and a coreceptor that is a member of the chemokine receptor 
family. The viral particles that initiate infection are usually in the blood, semen, or 
other body fluids of one individual and are introduced into another individual by 
sexual contact, needle stick, or transplacental passage. Env is a complex 
composed of a transmembrane gp41 subunit and an external, noncovalently 
associated gp120 subunit. The Env complex is expressed as a trimeric structure of 
three gp120/gp41 pairs. This complex mediates a multistep process of fusion of the 
virion envelope with the membrane of the target cell.  
The first step of this process is the binding of gp120 subunits to CD4 molecules, 
which induces a conformational change that promotes secondary gp120 binding to 
a chemokine coreceptor. This process induces a conformational change in gp41 
that exposes a hydrophobic region, called the fusion peptide, which inserts into the 
cell membrane and enables the viral membrane to fuse with the target cell 
membrane (fig. 9).  
Once an HIV virion enters a cell, the nucleoprotein core of the virus becomes 
disrupted, the RNA genome of HIV is transcribed into a double-stranded DNA form 
by viral reverse transcriptase and the viral DNA enters the nucleus. The viral 
integrase also enters the nucleus and catalyzes the integration of viral DNA into the 
host cell genome. The integrated HIV DNA is called provirus and may remain 
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transcriptionally inactive for months or years, with little or no production of new viral 
proteins or virions. Transcription of the genes of the provirus is regulated by the 
LTRs upstream of the viral structural genes, and cytokines or other physiologic 
stimuli to T-cells and macrophages enhance viral gene transcription. The LTRs 
contain polyadenylation signal sequences, the TATA box promoter sequence and 
binding sites for two host cell transcription factors, NF-κB and SP1. Initiation of HIV 
gene transcription in T-cells is linked to activation of the T-cells by antigens or 
cytokines. 
 
 
Figure 9 - HIV-1 entry in host cells [Kumar V., Robbins Basic Pathology, 2007] 
 
Tat protein is required for HIV gene expression and acts by enhancing the 
production of complete viral mRNA transcripts. Tat binds to the nascent mRNA and 
increases the "processivity" of RNA polymerase by several hundred-fold. 
The mRNAs encoding the various HIV proteins are derived from a single full-
genome-length transcript by differential splicing events (fig. 10).  
The Rev, Tat, and Nef proteins are early gene products encoded by fully spliced 
mRNAs that are exported from the nucleus and translated into proteins in the 
cytoplasm soon after infection of a cell. Late genes include env, gag, and pol, 
which encode the structural components of the virus and are translated from singly 
spliced or un-spliced RNA. The Rev protein initiates the switch from early to late 
gene expression by promoting the export of these incompletely spliced late gene 
RNAs out of the nucleus. The pol gene product is a precursor protein that is 
sequentially cleaved to form reverse transcriptase, protease, ribonuclease, and 
integrase enzymes. The gag gene encodes a 55-kD protein that is proteolytically 
cleaved by the viral protease into p24, p17 and p15 polypeptides, which are the 
core proteins required for assembly of infectious viral particles. The primary 
product of the env gene is a 160-kD glycoprotein (gp160) that is cleaved by cellular 
proteases within the endoplasmic reticulum into the gp120 and gp41 proteins 
required for HIV binding to cells.  
Assembly of infectious viral particles then begins by packaging full-length RNA 
transcripts of the proviral genome within a nucleoprotein complex that includes the 
gag core proteins and the pol-encoded enzymes required for the next cycle of 
integration. This nucleoprotein complex is then enclosed within a membrane 
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envelope and released from the cell by a process of budding from the plasma 
membrane. The rate of virus production can reach sufficiently high levels to cause 
cell death. In addition, gp120 and gp41, which are expressed on the plasma 
membrane of infected cells before virus is released, can mediate cell-cell fusion 
with an uninfected cell that expresses CD4 and coreceptors, and HIV genomes can 
then be passed between the fused cells directly. 
 
 
 
Figure 10 – Genomic structure of HIV-1 [Hoffmann C, HIVbook]  
 
HIV is transmitted via mucosal surfaces. Major groups at risk for the development 
of AIDS include homosexual or bisexual persons, intravenous drug abusers, 
heterosexual partners of members of other risk groups and babies born of infected 
mothers. Health care workers have a small increased risk for infection. 
Different isolates of HIV have distinct tropisms for different cell populations that are 
related to the specificity of gp120 variants for different chemokine receptors. All 
HIV strains can infect and replicate in freshly isolated human CD4
+
 T-cells that are 
activated in vitro. In contrast, some strains will infect primary cultures of human 
macrophages but not continuous T-cell lines (macrophage-tropic, or M-tropic, 
virus), whereas other strains will infect T-cell lines but not macrophages (T-tropic 
virus). Some virus strains also infect both T-cell lines and macrophages (dual-tropic 
virus). Macrophage-tropic virus isolates express a gp120 that binds to CCR5, 
which is expressed on macrophages (and some memory T-cells), whereas T cell-
tropic viruses bind to CXCR4, which is expressed on T-cell lines. In many HIV-
infected individuals, there is a change from the production of virus that uses CCR5 
and is predominantly macrophage tropic early in the disease to virus that binds to 
CXCR4 and is T-cell line tropic late in the disease. The T-tropic strains tend to be 
more virulent, presumably because they infect and deplete T-cells more than do M-
tropic strains. 
HIV disease begins with acute infection, which is only partly controlled by the 
adaptive immune response, and advances to chronic progressive infection of 
peripheral lymphoid tissues (fig. 11). Acute infection is characterized by infection of 
memory CD4
+
/CCR5
+
 T-cells in mucosal lymphoid tissues, and death of many 
infected cells. Because the mucosal tissues are the largest reservoir of T cells in 
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the body, and the major site of residence of memory T-cells, this local loss is 
reflected in considerable depletion of lymphocytes. The transition from the acute 
phase to a chronic phase of infection is characterized by dissemination of the virus, 
viremia and the development of host immune responses. DCs in epithelia at sites 
of virus entry capture the virus and then migrate into the LNs. DCs express a 
protein with a mannose-binding lectin domain that may be particularly important in 
binding the HIV envelope and transporting the virus. Once in lymphoid tissues, 
DCs may pass HIV on to CD4
+
 T-cells through direct cell-cell contact. Within days 
after the first exposure to HIV, viral replication can be detected in the LNs. This 
replication leads to viremia, during which large numbers of HIV particles are 
present in the patient's blood, accompanied by an acute HIV syndrome that 
includes a variety of nonspecific signs and symptoms typical of many viral 
diseases. 
 
 
 
Figure 11 - Typical course of HIV infection [Rowland-Jones S.L., Nat Rev Imm, 2003] 
 
The viremia allows the virus to disseminate throughout the body and to infect 
helper T-cells, macrophages and DCs in peripheral lymphoid tissues. As the HIV 
infection spreads, the adaptive immune system mounts both humoral and cell-
mediated immune responses directed at viral antigens. These immune responses 
partially control the infection and viral production, and such control is reflected by a 
drop in viremia to low but detectable levels by approximately 12 weeks after the 
primary exposure. In the next, chronic phase of the disease, LNs and the spleen 
are sites of continuous HIV replication and cell destruction. Although the majority of 
peripheral blood T-cells does not harbour the virus, destruction of CD4
+
 T-cells 
within lymphoid tissues steadily progresses during the latent period, and the 
number of circulating blood CD4
+
 T-cells steadily declines. As the disease 
progresses, patients become susceptible to other infections, and immune 
responses to these infections may stimulate HIV production and accelerate the 
destruction of lymphoid tissues. HIV disease progresses to the final lethal phase, 
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called AIDS, when the blood CD4
+
 T-cell count drops below 200 cells/mm
3
. HIV 
viremia may climb dramatically as viral replication in other reservoirs accelerates 
unchecked. Patients with AIDS suffer from combinations of opportunistic infections, 
neoplasms, cachexia (HIV wasting syndrome), kidney failure (HIV nephropathy), 
and CNS degeneration (AIDS encephalopathy). 
Macrophages express much lower levels of CD4 than helper T-cells do, but they do 
express CCR5 coreceptors and are susceptible to HIV infection. However, because 
macrophages can be infected but are relatively resistant to the cytopathic effects of 
HIV, they may become a reservoir for the virus. DCs can also be infected by HIV 
but are not directly injured by HIV infection. However, these cells form intimate 
contact with naϊve T-cells during the course of antigen presentation and may thus 
be an important pathway for T-cell injury. FDCs in the germinal centres of LNs and 
the spleen trap large amounts of HIV on their surfaces, in part by Fc receptor-
mediated binding of antibody-coated virus, and can infect macrophages and CD4
+
 
T-cells in the LNs. HIV infection results in impaired function of both the adaptive 
and innate immune systems.  
An important cause of the loss of CD4
+
 T-cells in HIV-infected people is the direct 
cytopathic effect of infection of these cells by HIV. Mechanisms in addition to direct 
lysis of infected CD4
+
 T-cells by virus have been proposed for the depletion and 
loss of function of these cells in HIV-infected individuals.  
Chronic activation of the T-cells may predispose the cells to apoptosis and 
apoptotic death of activated lymphocytes may account for the observation that the 
loss of T-cells greatly exceeds the numbers of HIV-infected cells. HIV-specific 
CTLs are present in many patients with AIDS, and these cells can kill infected 
CD4
+
 T-cells. In addition, antibodies against HIV envelope proteins may bind to 
HIV-infected CD4
+
 T-cells and target the cells for ADCC. Binding of gp120 to newly 
synthesized intracellular CD4 may interfere with normal protein processing in the 
endoplasmic reticulum and block cell surface expression of CD4, making the cells 
incapable of responding to antigenic stimulation. HIV-specific humoral and cell-
mediated immune responses develop following infection but generally provide 
limited protection, primarily because of the depletion and functional inhibition of the 
CD4
+
 T-cells. The initial adaptive immune response to HIV infection is 
characterized by expansion of CD8
+
 T-cells specific for HIV peptides, which 
nevertheless prove ineffective because of the emergence of viral escape mutants 
(variants with mutated antigens).  
Antibody responses to a variety of HIV antigens are detectable within 6 to 9 weeks 
after infection. The most immunogenic HIV molecules that elicit antibody responses 
appear to be the envelope glycoproteins, and high titers of anti-gp120 and anti-
gp41 antibodies are present in most HIV-infected individuals. Other anti-HIV 
antibodies found frequently in patients' sera include antibodies to p24, reverse 
transcriptase, and gag and pol products. The early antibodies are not neutralizing, 
and are generally poor inhibitors of viral infectivity or cytopathic effects. 
Neutralizing antibodies against gp120 develop 2 to 3 months after primary 
infection, but even these antibodies cannot cope with a virus that is able to rapidly 
change the most immunodominant epitopes of its envelope glycoproteins. 
The failure of cell-mediated and humoral immune responses to eradicate HIV 
infection is probably due to several factors. Notably HIV has an extremely high 
mutation rate because of error-prone reverse transcription, and in this way it may 
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evade detection by antibodies or T-cells generated in response to viral proteins. 
Active research efforts have been aimed at developing reagents that interfere with 
the viral life cycle. Treatment of HIV infection and AIDS now includes the 
administration of three classes of antiviral drugs, used in combination, that target 
viral molecules for which no human homologues exist.  
The first type of drug to be widely used consists of nucleoside analogues that 
inhibit reverse-transcriptase activity. These drugs include deoxythymidine 
nucleoside analogues such as 3'-azido-3'-deoxythymidine (AZT), deoxycytidine 
nucleoside analogues, and deoxyadenosine analogues. When these drugs are 
used alone, they are often effective in significantly reducing plasma HIV RNA levels 
for several months to years. They usually do not halt progression of HIV-induced 
disease, largely because of the evolution of virus with mutated forms of reverse 
transcriptase that are resistant to the drugs.  
More recently, viral protease inhibitors have been developed that block the 
processing of precursor proteins into mature viral capsid and core proteins. When 
these protease inhibitors are used alone, mutant viruses resistant to their effects 
rapidly emerge. However, protease inhibitors are now being used in combination 
with two different reverse-transcriptase inhibitors. This new triple-drug therapy, 
commonly referred to as HAART (highly active antiretroviral therapy), has proved 
to be remarkably effective in reducing plasma viral RNA to undetectable levels in 
most treated patients for up to 3 years. An integrase inhibitor is also now used as 
part of anti-viral therapy. Although anti-retroviral therapy has reduced viral titers to 
below detection for up to 10 years in some patients, it is unlikely that such 
treatment can eliminate the virus from all reservoirs, especially long-lived infected 
cells, and resistance to the drugs may ultimately develop. Other problems 
associated with these new drug therapies, which will impair their effective use in 
many parts of the world, include high expense, complicated administration 
schedules and serious side effects. Although there have been numerous 
approaches for generating HIV vaccines in the past 20 years, to date there is no 
approved vaccine on the market.  
2.3. Innate Immunity to viral infections  
Virus invasion initially activate innate immune system that set up robust antiviral 
responses. Host cells detect, through pattern-recognition receptors (PRRs), 
specific viral components, such as genomic DNA, single-strand RNA (ssRNA), 
double-strand RNA (dsRNA), RNA with 5’-triphosphate ends and viral proteins [55]. 
Currently, three classes of PRRs are implicated in viral component recognition, 
Toll-like receptors (TLRs), retinoic acid-inducible gene I (RIG-I)-like receptors 
(RLRs), and nucleotide oligomerization domain (NOD)-like receptors (NLRs) (fig. 
12). Among these receptors, TLRs and RLRs are important for the production of 
type I interferons (IFNs) and cytokines, whereas NLRs are involved in the 
production of interleukin-1β (IL-1β) [56].  
Intracellular signaling cascades activated by type I IFNs results in the regulation of 
a wide range of IFN-inducible genes (ISGs), involved in eliminating viral 
components from infected cells, inducing apoptosis of infected cells and conferring 
resistance to viral infection on uninfected cells. Type I IFNs are produced not only 
by professional innate immune cells, including dendritic cells (DCs) and 
macrophages, but also by non-professional cells. Proinflammatory cytokines and 
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chemokines are also critical in eliminating virus infection by causing inflammation 
and recruiting innate and acquired immune cells. Costimulatory molecules are 
essential for T cell activation leading to acquired immune responses. 
 
 
 
Figure 12 - Innate immune sensors [Theofilpoulus A.N., Nature Reviews Rheum, 2010] 
2.3.1. Innate immunity sensors 
2.3.1.1. The RLR signaling pathway 
RLRs consist of a family of cytoplasmic protein comprising of three members, RIG-
I, melanoma differentiation-associated gene 5 (MDA5), and laboratory of genetics 
and physiology-2 (LGP2) [57]. RIG-I and MDA5 consist of two N-terminal caspase-
recruitment domains (CARDs), a DExD/H box RNA helicase domain, and a C-
terminal repressor domain (RD), although LGP2 lacks the CARD-like region [58].  
RNA virus infection leads to the generation of dsRNA and ssRNA with 5’-
triphosphate ends in infected cells, not usually present in host cells. Thus, RLRs 
located in the cytoplasm, recognize viral RNA. 
The recognition of these RNAs is mediated by the helicase domain and the RD 
while the CARDs are essential for eliciting downstream signaling pathway. The 
LGP2 domain, lacking a CARD, seems to function as a negative regulator [59, 60].  
RIG-I and MDA5 interact with viral RNA with different ligand specificity and elicit 
signaling leading to the transcription of type I IFN and inflammatory cytokines. In 
response to detection of viral RNAs, RIG-I and MDA5 associate with the adapter 
protein IFNβ promoter stimulator-I (IPS-1), also known as mitochondrial antiviral 
signaling (MAVS) [61, 62] (fig. 13).  
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Figure 13 – RIG-I-like receptor pathway [Baccala R., Nature Med. 2007] 
 
Virus-specific RNA species specifically bind to RIG-I through its RNA binding 
domain. This complex in presence of ATP induce a conformational change of RIG-I 
that allows the CARD domain to bind IPS-1 on the outer membrane of 
mitochondria [63]. Tumor necrosis factor receptor (TNFR)-associated death 
domain (TRADD) protein is recruited to IPS-1 upon stimulation and forms a 
complex with Fas-associated death domain-containing protein (FADD) and a death 
domain kinase receptor-interacting protein 1 (RIP1), in addition to TNF-receptor 
associated factor 3 (TRAF3) [64, 65].  
Downstream of TRAF3, two IB kinases (IKK)-related kinases, TKB1 (TANK-
binding kinase 1) and inducible IB kinase (IKK-i), phosphorylate the IFN-
regulatory factor-3 (IRF3) and IRF7 [66, 67]. The activation of IRF3/7 by these 
kinases induces the formation of homodimers and/or heterodimers that 
translocate into the nucleus and bind to IFN-sensitive response elements (ISREs), 
resulting in the expression of type I IFNs and a set of IFN-inducible genes [68]. 
The RLR signaling pathway activates another transcription factor, NF-B for the 
expression of pro-inflammatory genes. IPS-1, TRADD and FADD are important 
for activating both IRFs and NF-B [69]. FADD interacts with caspase-8/-10, and 
the catalytic activities of these caspases are critical for the subsequent nuclear 
translocation and activation of NF-B.  
A recent study identified a novel protein named stimulator of IFN genes (STING) 
as an important molecule for RIG-I/MDA5 signaling [70]. Overexpression of 
STING activated NF-B and ISRE via TBK1/IKK-i. 
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2.3.1.2. Recognition of viral component by TLR system 
TLRs represent a group of PPRs located on cell surface or within endosomes 
suitable for detecting viral components outside of cells as well as in cytoplasmic 
vacuoles after phagocytosis or endocytosis [71]. TLRs are type I integral 
membrane receptors and comprise an ectodomain, which contains leucine-rich 
repeats that mediate the recognition of pathogen-associated molecular patterns 
(PAMPs), a transmembrane region, and cytosolic Toll-IL-1 receptor (TIR) domains 
that activate downstream signaling pathway [55]. To date, ten TLRs have been 
identified in humans. Each TLR detects distinct PAMPs derived from viruses, 
bacteria, mycobacteria, fungi and parasites. These include lipoproteins (recognized 
by TLR1, TLR2 and TLR6), dsRNA (TLR3), lipopolysaccharide (LPS) (TLR4), 
bacterial flagellin (TLR5), viral or bacterial ssRNA (TLRs 7 and 8), and CpG-rich un 
methylated DNA (TLR9) [72]. TLR1, TLR2, TLR4, TLR5, and TLR6 are localized on 
the cell surface and largely recognize microbial membrane components whereas 
TLR3, TLR7, TLR8, and TLR9 are expressed within intracellular vesicles and 
recognize nucleic acids [73]. The intracellular localization enables TLRs to 
recognize nucleic acids delivered to the intracellular compartments after the uptake 
of viruses and other pathogens or infected cells. By contrast, cellular nucleic acids 
within the extracellular compartment, are rapidly degraded by nucleases and do not 
access intracellular vesicles. TLR3, TLR7, TLR8, and TLR9 are sequestered in the 
ER and are delivered to the endosomes where their N-terminal region  is 
processed by multiple lysosomal proteases, including cathepsins and asparagine 
endopeptidase, to generate functional receptors that elicit signaling [73, 74].  
After the recognition of specific PAMPs, TLRs recruit a set of adaptor molecules 
that harbor TIR domain and initiate downstream signaling events, leading to the 
secretion of inflammatory cytokines, type I IFN, and chemokines [75].These 
responses cause recruitment of neutrophilis, activation of macrophages and 
induction of IFN-stimulated genes, resulting in direct killing of the infected 
pathogens. Furthermore, activation of TLR signaling contributed to the induction of 
adaptative immunity by leads inducing DCs maturation.(fig. 14). 
The specific response originated by individual TLRs depends on the recruitment of 
a single, or a specific combination of TIR-domain-containing adaptor protein such 
as myeloid differentiation primary response protein 88 (MyD88), TIR domain-
containing adapter protein (TIRAP), TIR domain-containing adapter inducing IFN- 
(TRIF or TICAM) or Trif-related adapter molecule (TRAM). All TLRs, except TLR3, 
activate a common signaling pathway leading to the production of proinflammatory 
cytokines via myeloid differentiation factor 88 (MyD88), a central adapter protein.  
The association between TLRs and MyD88 recruits members of the interleukin-1 
receptor-associated kinase (IRAK) family. To date, four IRAKs are identified: 
IRAK1, IRAK2, IRAK4 and IRAK-M [76, 77, 78]. While IRAK1 and IRAK4 possess 
intrinsic serine/threonine protein kinase activities, IRAK2 and IRAK-M lack this 
activity, suggesting that they are negative regulator.  
In response to stimuli, IRAK4 and IRAK1 are sequentially phosphorylated and 
dissociated from MyD88, which results in activation of tumor necrosis factor 
receptor-associated factor 6 (TRAF6) which forms a complex with UBC13 and 
UEV1A [79]. TRAF6 in turn activates transforming growth factor--activated protein 
kinase 1 (TAK1), a member of the MAP kinase (MAP3K) family, in a ubiquitin-
dependent manner [79]. TAK1 forms a complex with TAB1, TAB2 and TAB3 and 
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activates the IKK complex that leads to NF-B activation [79]. TAK1 simultaneously 
phosphorylates two members of the MAP kinase family, MKK3 and MKK6, which 
successively activate JNK and p38. ERK is also activated in response to TLR 
ligands through the activation of MEK1 and MEK2, although an upstream kinase 
activating MEK1 and MEK2 in TLR signaling remains unknown. The signaling 
pathway from MyD88 to the activation of NF-B and AP-1 is used by almost all 
TLRs to control inflammatory responses. However, the activation of the MyD88-
dependent pathway requires an additional adapter TIRAP/Mal in terms of TLR2 
and TLR4 signaling [80, 81]. 
 
 
 
Figure 14 – TLRs trafficking and signaling [Kawai T., Immunity, 2011] 
 
TLR3 and TLR4 recruits another adaptor protein TIR domain-containing adapter 
inducing IFN (TRIF) (also known as TICAM-1), which leads to induction of type I 
IFN[82]. TRIF associates with TRAF3 and TRAF6 and subsequently with RIP1 and 
RIP3 [83, 84]. Recent studies showed that TRADD is also involved in the TRIF-
dependent signaling pathway [85]. The downstream signaling molecules for the 
expression of IFN-inducible genes are shared between the TLR3 and RLR 
signaling pathways. Simultaneously, TRAF6 and RIP1 are responsible for 
activating NF-B through IKK/, leading to the expression of proinflammatory 
cytokines. Transcription of IFN gene is tightly controlled by cooperative activation 
of several transcription factors, including NF-B, ATF2/c-Jun, interferon regulatory 
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factor (IRF)3 and IRF7 [86]. While NF-B and ATF2/c-Jun are activated by 
numerous stimuli such as TLR ligands, IL-1, TNF and DNA damage, IRF3 and 
IRF7 are activated when cells are exposed to LPS, poly IC and virus infection, and 
mainly control type I IFN. IRF3 and IRF7 are structurally related proteins present in 
the cytoplasm in unstimulated conditions. TLR7 and TLR9 activate distinct 
signaling pathways in response to viral RNA or DNA in pDC. TLR7 and TLR9 
recruit MyD88, which forms a complex with IRAK-1, IRAK-4, and IRF-7 in this cell 
type [87]. IRAK-1 and IKK have been identified as potential IRF-7 kinases [88]. 
Phosphorylated IRF-7 translocates into the nucleus to activate the promoters of 
type I IFN and IFN-inducible genes. The MyD88-dependent pathway is also critical 
for NF-B, leading to the production of cytokines including IL-12 and IL-6.  
Localizations of TLR proteins are critical for the recognition of their ligands. An ER 
protein, UNC93B, was identified as an essential molecule for the translocation of 
TLR7 and TLR9 from the ER to endosomes [89]. Another ER protein associated 
with TLR4 (PRAT4A) also control TLR9 trafficking from the ER to 
endosome/lysosomes [90]. Collectively, recognition of viral nucleotides by TLRs in 
endosome/lysosomes is controlled by the localizations of TLRs as well as their 
ligands. This elaborate mechanism may be essential for preventing autoimmune 
diseases caused by aberrant initiation of TLR signaling.  
2.3.1.3. Role of NLRs and inflammasomes 
NLRs are a large receptor family that is characterized by the presence of a 
conserved nucleotide binding oligomerization domain (NOD) motif. Structurally, 
NLRs consist of an N-terminal protein–protein interaction domains such as the 
caspase-recruitment domain (CARD), pyrin domain (PYD) or baculovirus inhibitor 
repeat (BIR) domain; an intermediary NOD domain which is an ATP-binding 
domain needed for nucleotide binding and self-oligomerization; and an array of C-
terminal leucine-rich repeat (LRR) motifs that are presumed to detect conserved 
microbial patterns and to modulate NLR activity [91] (fig. 15).  
 
 
 
Figure 15 – NLRs structure [modified from Meylan E., Nature, 2006] 
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To date, twenty two NLR genes are found in human genome. When a PAMP is 
sensed by the C-terminal LRR motifs of an NLR, the molecule undergoes 
conformational changes that trigger oligomerization through the NOD. In turn, 
NLRs expose the N-terminal effector domains to induce the recruitment and 
activation of CARD- and/or PYD-containing effector molecules [92]. As a result, 
NLRs are involved in the activation of multiple signaling pathways. The NLR 
proteins NOD1 and NOD2 interact with the receptor-interacting serine-threonine 
protein kinase 2 (RIPK2; also known as RICK or RIP2) to induce NF-B and MAPK 
signalling. NOD2 also associates with IPS1 for the induction of type I IFNs in 
response to viral infection [92]. 
Moreover, NLRs are involved in the activation of a large protein complex known as 
inflammasome that results in caspase-1 mediated cleavage of pro-interleukin 1 
(IL-1β) and pro-IL-18 into their active form. The activation of caspase-1 is triggered 
by NLRP3 and ICE-protease-activating factor (IPAF), together with an adapter, 
ASC (apoptosis-associated speck-like protein containing a CARD) [93] (fig. 16).  
 
 
 
 
Figure 16 – NLRP3 inflammasome complex activation [Tschopp J., Nat. Rewiev Imm.2010] 
 
Moreover, NLRP3 is responsible for sensing presence of ATP as well as various 
crystals by phagocytosis [94, 95]. Although mechanisms of crystal recognition by 
NALP3 is not fully understood, recent studies suggest that NLRP3 activation is 
triggered by reaction oxygen species (ROS) produced by a nicotinamide adenine 
dinucleotide phosphate oxidase or by lysosomal destabilization which may release 
protease cathepsin B to the cytosol [96-97]. dsRNA and polyI:C were reported to 
activate the inflammasome via a NLRP3-dependent pathway, but it remains 
unclear whether NLRP3 directly recognizes dsRNA in the cytoplasm [98]. 
Moreover, ASC and caspase-1 are essential for dsDNA-induced IL-1 production, 
suggesting that one of the unknown NALP family members functions as a 
cytoplasmic DNA sensor. Although a role for NLRP3 in sensing viruses has been 
proposed, the precise molecular mechanism remains poorly understood. Several 
lines of evidence indicate that the NLRP3 inflammasome might detect the presence 
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of viral RNA and DNA in intracellular compartments [99]. The discovery that 
NLRP3 can detect a wide range of divergent PAMPs, such as bacterial LPS, 
peptidoglycan and bacterial or viral nucleic acids, as well as endogenous danger 
signals (DAMPs), such as monosodium urate (MSU), calcium pyrophosphate 
dihydrate and ATP, has led to the hypothesis that NLRP3 might sense a common 
downstream effect caused by these molecules, rather than the PAMPs or DAMPs 
themselves. However, not all NLRs are proinflammatory. NLRP12 and NLRP6 
have been shown to downregulate NF-B signalling subsequent to TLRs activation 
[100]. NLRP12 has also been reported to regulate alternative NF-B signaling 
downstream of TNF family receptors like CD40. Finally, NLR family member X1 
(NLRX1) and NLRC5 have been shown to inhibit NF-B and type I IFN signalling 
pathways, indicating that these NLRs have an important role as negative regulators 
[101]. 
2.3.2. Antiviral mediator and effector molecules 
2.3.2.1. Type I IFN-producing cells in response to viral infections  
The IFNs are a large family of secreted cytokines involved in antiviral response and 
immune activation. The IFN family includes two main classes of related proteins 
characterized by structural homology. Type I IFNs are produced in direct response 
to virus infection and comprise products of the IFNα family, predominantly 
synthesized by leukocytes and plasmacytoid dendritic cells (pDC) and products of 
the IFNβ gene, synthesized by most cell types and in particularly by fibroblasts 
[102]. Type II IFN consists of the product of the IFN gene produced in response to 
the recognition of infected cells by activated T lymphocytes and natural killer (NK) 
cells [103]. Both the type I and type II IFN receptors have multichain structures 
composed of distinct subunits: IFNAR1 and IFNAR2 for the type I IFN receptor, and 
IFNGR1 and IFNGR2 for the type II IFN receptor. Each subunits interacts with a 
member of the Janus activated kinase (JAK) family [104]. In particular, the IFNAR1 
subunit is constitutively associated with tyrosine kinase 2 (TYK2), IFNAR2 and 
IFNGR1 are associated with JAK1 and finally IFNGR2 is constitutively associated 
with JAK2 [105]. The initial phase in both type I and type II IFN mediated response 
is the rearrangement and dimerization of the receptor subunits followed by 
autophosphorylation of the associated JAKs. This activation seems to regulate, 
either directly or indirectly, several other downstream cascades. Multiplicity of 
signaling is consistent with the pleiotropic biological effects of IFNs on target cells 
and tissue [105, 106].  
2.3.2.2. STATs and Interferon Stimulated Genes (ISGs) 
Binding of IFNα or other type I IFNs to their related receptors causes the activation 
of the receptor-associated JAKs, TYK2 and JAK1, which in turn trigger 
phosphorylation and consequently activation of signal transducers and activators of 
transcription (STATs) [107]. The induction of STAT1, STAT2, STAT3 and STAT5 is 
a common response to different type I IFNs. STAT4 and STAT6 can also be 
activated by IFNα, but only in endothelial cells or cells of lymphoid origin [108, 
109]. After phosphorylation by JAKs, the activated STATs form homodimers or 
heterodimers that translocate to the nucleus and started transcription by binding 
specific sites in the promoters of IFN-stimulated genes (ISGs) [107-109]. An 
important transcriptional complex that is induced by type I IFNs is the ISG Factor 3 
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(ISGF3) complex, constituted of the phosphorylated forms of STAT1 and STAT2, 
together with IRF9 [107]. This complex is the only one that binds specific elements 
known as IFN-stimulated response elements (ISREs) that are present in the 
promoters of specific ISGs, thereby initiating their transcription. Other STAT 
complexes  bind another type of element, known as an IFN--activated site (GAS) 
element, that is present in the promoter of different ISGs [110]. 
Of the hundreds of known ISGs, some have only ISREs or only GAS elements in 
their promoters, whereas others have both elements; therefore, combinations of 
different STAT-containing complexes regulates the optimal transcription of a 
particular gene. Notably, specific responses might be explained by the modulation 
of distinct STATs functions. The transcription of type II IFN (IFN)-dependent 
genes is regulated by GAS elements, and STAT1 is the most important IFN--
activated transcription factor [107-110]. The activation of JAK1 and JAK2 regulate 
STAT1 phosphorylation, leading to the formation of STAT1–STAT1 homodimers, 
which translocate to the nucleus and bind GAS elements. In contrast to type I IFNs, 
IFN-γ does not induce the formation of ISGF3 complexes and thereby cannot 
induce transcription of genes that have only ISREs in their promoter [111] (fig. 17). 
 
 
 
Figure 17 – IFN receptors and JAK/STAT pathway [Platanias L.C., Nat Rev Imm, 2005] 
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Importantly, both type I and type II IFNs can induce the recruitment of STAT3. 
Following its phosphorylation, STAT3 forms homodimers that translocate to the 
nucleus, where they bind to STAT3-binding elements (SBEs). STAT1 and STAT3 
have a high level of sequence similarity but the sets of genes that are activated by 
these two factors are different and exert opposing effects. In particular, IFN-γ-
dependent STAT1 activation usually mediates a pro-inflammatory response that 
promotes immune cell recruitment through upregulation of adhesion molecule 
expression (e.g., ICAM-1, VCAM-1), the production of pro-inflammatory mediators 
(e.g., IP-10, MCP-1, MIG, MIP-1α/β, RANTES) and the enhancing of antigen 
processing and presentation by MHC class I and II molecules [111]. By contrast, 
STAT3 is a key mediator of IL-10 signaling [112], which negatively regulates pro-
inflammatory responses by directly inhibiting STAT1 activation.  
IFN effectors vary widely in their magnitude of inhibitory activity and display 
combinatorial antiviral properties [Tab. 3]. Collectively, ISGs can target almost any 
step in a virus life cycle. Some of the most potent antiviral effectors reinforce the 
system by further inducing IFN or ISGs. Other genes enhance or facilitate viral 
replication, suggesting that some viruses cooperate with IFN effectors for a survival 
advantage. 
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Table 3 - Antiviral ISGs [modified from Schoggins J.W., Elsevier 2011] 
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2.3.2.3. Intrinsic immunity to influenza virus 
Epithelial cells in the respiratory tract are the primary target of influenza virus. 
Macrophages and DC can also be infected by FLU virus and play an important 
role in host innate and adaptive immune responses to the virus. Influenza virus 
can be identified by various PRRs, including RLR, TLR and NLR (fig. 19).  
 
 
 
Figure 19 – Intrinsic antiviral immunity against Influenza Virus [Yan N., Nat Imm, 2012]  
 
In infected fibroblasts, the cytosolic RNA sensor RIG-I recognizes 5'-triphosphate 
of influenza virus genomic RNA and enhances IFN production through MAVS and 
IRF3. By contrast, viral protein NS1 helps the virus to evade innate immune 
detection by sequestering viral RNA or by binding to RIG-I and/or other protein 
required for RIG-I cascade [113]. In pDC, the endosomal TLR7 recognize 
influenza virus ssRNA resulting in proinflammatory cytokines and IFN production 
[114]. Moreover, FLU virus prompts IL-1β production by increasing pro-IL-1β and 
NLRP3 transcription(signal 1) and by activating NLRP3 inflammasomes (signal 2) 
[115, 116]. Signal 1 is triggered by the activation of NF-B as a consequence of 
viral RNA detection by TLR7. Signal 2 is provided by several sources that all 
depend on viral M2 protein, including ionic imbalance of trans-Golgi pH, 
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potassium efflux through the P2X7 receptor ion channel, and elevation of cellular 
reactive oxygen species (ROS). Studies found that the inflammasome complex is 
dispensable for viral clearance.[115, 116]. 
2.3.2.3.1. The IFITM family 
The interferon induced transmembrane (IFITM) genes belong to a family of small 
ISGs containing IFITM1, 2 and 3. IFITM3 has been found in genome-wide 
screens as a host restriction factor for influenza A virus [117, 118]. Although the 
mechanism remain to be clarify, the expression of IFITM genes is induced by 
influenza virus, inhibiting viral entry into target cells.[117]. Moreover, IFITM 
proteins also obstacle the replication of some flaviviruses, including dengue virus 
and West Nile virus [117]. Induction of IFITM gene expression has also been 
observed as a consequence of cytomegalovirus (CMV) and herpes simplex virus 
(HSV) infection, although there is no established evidence for an antiviral role of 
these proteins against DNA viruses [119].  
IFITM proteins have also been implicated in cancer [120]. Studies have shown 
that IFITM1 and 3 are associate with cell surface antigen CD81, a protein found 
to be differently expressed in a variety of cancers. Moreover, all IFITM proteins 
contain a conserved CD225 domain with antiproliferative activity that can be 
enhanced by IFNs treatment [121].  
Comparison of genes encoding IFITM proteins of different organisms has shown 
higher than normal sequence variation suggesting that these genes are under 
positive selection during evolution [120]. Taken together, IFITM proteins 
represent interesting targets for therapeutical approaches against virus and 
cancer. 
2.3.2.3.2. The IFIT family 
The IFN-induced protein with tetratricopeptide repeats (TPRs) (IFIT) family 
contains four members in humans, namely IFIT1 (ISG56), IFIT2 (ISG54), IFIT3 
(ISG60) and IFIT5 (ISG58). All IFIT proteins are cytoplasmic proteins that contain 
multiple helix-turn-helix structures (TPRs) involved in protein-protein interactions 
and protein complexes assemblation [122]. IFIT1 was originally found to inhibit 
cellular translation by binding the eIF3 initiation factor as a consequence of the 
non-specific antiviral response mediated by IFN [105].  
IFIT1 also prevents cytoplasmic sensing of viral RNA by binding the adaptor 
protein STING thereby disrupting signaling cascade [124]. This negative 
feedback of IFN signaling regulated by IFIT1 is important for preserving host cell 
from toxicity caused by an excessive IFN-production. 
Recently, IFIT proteins were found to recognize viral RNA that contains a 5'- 
triphosphate (5'-ppp) moiety or lacks 2'-O-methylation [125, 126]. Cellular mRNA 
usually contains a 5'-guanosine cap, necessary requirement for mRNA 
stabilization and discrimination between self and non-self RNAs. In addition, 
cellular mRNAs are also methylated at the 2'-O position, whose role remain 
unclear. Many RNA viruses also encode a methyltransferase that methylates the 
2'-O position of viral RNA to mimic host mRNA. This modification is important for 
these viruses to evade host restriction by IFIT proteins. Viruses defective in 
methyltransferase exhibited enhanced sensitivity to IFN treatment in an IFIT- 
dependent manner [125, 126]. Thus, 2'-O-methylation of host mRNAs is critical 
Introduction 
 
34 
 
for self versus non-self discrimination for at least some RNA viruses.  
IFIT1 also binds viral genomic RNA containing 5'-ppp, similar to RIG-I, and exerts 
a direct antiviral activity [127]. Instead of activating IFN, the binding of IFIT 
proteins to 5'-ppp viral RNA inhibits viral translation and replication. According to 
direct antiviral activity, knockdown of IFIT1 results in stronger viral replication 
without affecting the IFN response. To date, mechanisms of inhibition following 
recognition by IFIT proteins remain to be clarified. 
2.3.2.3.3 Human myxovirus-resistant protein 1 (MX1)  
The human myxovirus resistant protein 1 (MX1 or MXA) is a GTPase with wide 
antiviral activities. Notably, cytoplasmatic MX1 protein has found to exert antiviral 
activity against influenza virus infection, by blocking virus life cycle subsequently 
to transcription and viral replication [128]. Different strains of influenza virus vary 
in their sensitivity to MX proteins, which is determined by specific viral 
nucleoprotein (NP) [129, 130]. The structure of MXA seems to form an oligomeric 
ring structure around viral nucleocapsid, thereby inhibiting viral replication [131]. 
To date, how human MX1 can inhibit a broad spectrum of RNA viruses, some of 
which replicates in the nucleus, and whether MX1 acts by recognizing a common 
viral component or structure remains to be clarify 
2.3.2.4. Intrinsic immunity to HIV 
Mucosal innate immunity is the first line of defense against HIV-1 during early 
phases of infection, and it also plays a crucial role in the induction of adaptive 
immune responses. HIV-1 infection results in the activation of both cellular and 
intracellular innate immunity. Cellular innate immunity includes functions of DCs 
such as Langerhans cells that are amongst the first group of cells that contact HIV-
1 at the site of infection, and that can mediate trans-infection of CD4+ T cells [132]. 

+
 T cells offer innate responses to HIV through generating antiviral factors, such 
as RANTES, MIP-1α and MIP-1β [133]. Natural killer (NK) cells also play important 
roles in cellular innate immunity against HIV by eliminating infected cells and 
modulating DC functions [134]. Intracellular innate immunity includes several 
interferon-stimulated host factors that play important roles in restricting HIV-1 
replication, such as APOBEC3G, TRIM5α, Tetherin/BST-2 and SAMHD1 [135, 
136] (fig. 20). HIV-1 neutralizes some of these antiviral factors via its accessory 
proteins, and avoid upregulation of other antiviral ISGs in infected target cells 
[137]. 
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Figure 20 - Intrinsic antiviral immunity against HIV-1 [Yan N., Nat Imm, 2012] 
 
2.3.2.4.1 APOBEC3G 
APOBEC3G is one of the first identified intrinsic antiviral factors against HIV-1. It 
belongs to a family of cytidine deaminases that contains 7 members in primates 
(APOBEC3A, B, C, DE, F, G, and H). The main restriction factors for HIV-1are 
represented by APOBEC3G and 3F. These molecules are assembled into HIV-1 
virions through interaction with nucleocapsid portion of HIV Gag. Upon infection 
of target cells and during reverse transcription, APOBEC3G edits C→U in ssDNA 
(negative strand), which results in G→A mutation in the HIV genome. G→A 
mutations often results in premature stop codons that partially contributed to the 
reduced replication. Such G→A mutations are also frequently found in HIV DNA 
isolated from AIDS patients [138].  
APOBEC3G also inhibit reverse transcription and chromosomal integration 
through undefined mechanisms that are independent of its deaminase activity 
[139]. HIV-1 Vif counteracts APOBEC3G by promoting its ubiquitination by an E3 
ligase complex, thus allowing its degradation by the proteasome in virus 
producing cells [140]. 
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2.3.2.4.2 Tripartite motif family 5TRIM5 
TRIM5α, is a member of the tripartite motif family (TRIM) that shares a common 
organization at the N terminus containing a RING domain, a B-box domain and a 
coiled-coil domain. The RING domain is usually found in E3 ubiquitin ligase and 
the B-box domain determines substrate specificity. The C terminus of TRIM5α 
contains a B30.2 domain that binds to the capsid of the incoming virion and is 
important for restriction. The B30.2 domain of TRIM5α, is also determinant for 
retrovirus species tropism [141]. The importance of TRIM5α restriction activity was 
underlined again by the discovery of the TRIM5α-cyclophilin A (TRIMCyp) fusion 
protein in owl monkey cells [142]. TRIMCyp occurs naturally by in-frame fusion 
where CypA replaces the B30.2 domain. CypA also binds to the HIV-1 capsid and 
TRIM-Cyp potently restricts HIV-1 through mechanisms similar to TRIM5α. HIV-1 
restriction by these factors occurs early during replication, prior to reverse 
transcription, and likely during the process of uncoating [141]. TRIM5α promotes 
the rapid uncoating of HIV-1 capsids in vitro [143]. Accelerated disassembly of 
retroviral capsid may prematurely expose the viral RNA or viral enzymes to 
degradative processes or disrupt capsid associations with retroviral core that are 
directly or indirectly critical for reverse transcription.Moreover, TRIM5α was also 
found to promote innate immune signaling and to act as a PRR for capsid of many 
retroviruses, including MLV, HIV and SIV [144].  
2.3.2.4.3 Theterin 
Tetherin was discovered through characterization of HIV-1 accessory protein 
Vpu [145, 146] which enhances the release of HIV and other retroviral virions, 
thereby promoting replication. Structurally, tetherin consists of N terminal 
cytoplasmic domain, a transmembrane domain, extracellular long coiled-coil 
domain and a C terminal glycosylphosphatidylinositol (GPI) membrane anchor. 
The short cytoplasmic domain binds to the clathrin adaptors for endocytosis. 
Tetherin is thought to retain virions at the cell surface, by introducing the GPI 
membrane anchor into the virion envelope or by dimerization of two tetherins 
each anchoring at the host cell membrane and the virion envelope, respectively. 
Thus, tethered virions are internalized by endocytosis and subsequently 
degraded in the endosomes [147]. Vpu promotes the degradation of tetherin, 
thereby facilitating HIV infection.  
Tetherin targets many other enveloped viruses, such as other retroviruses (MLV, 
HTLV-1), filoviruses (Ebola virus), and herpesvirus (KSHV) [147]. Each of these 
viruses encode a viral protein that binds to tetherin and promotes its degradation 
or inhibits its function through an unknown mechanism. Tetherin also plays a role 
in immune cell signaling. In fact, tetherin binds to ILT7 (immunoglobulin-like 
transcript 7), a membrane receptor selectively expressed in pDC leading to the 
inhibition of TLR-mediated IFN responses in pDCs [148]. Tetherin is also 
involved in NF- B activation [149]. The implication of this mechanism in viral 
infection need further studies. 
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2.3.2.4.4 SAMHD1 and TREX 
SAMHD1 restricts the infection of dendritic and other myeloid cells by human 
immunodeficiency virus type 1 (HIV-1), but in lentiviruses of the simian 
immunodeficiency virus of sooty mangabey (SIVsm)–HIV-2 lineage, SAMHD1 is 
counteracted by the virion-packaged accessory protein Vpx. HIV-1 does not 
encode Vpx, and Vpx-deficient SIVmac or HIV-2 fails to replicate in DC. 
SAMHD1 appears to inhibit HIV-1 reverse transcription and innate immune 
responses to HIV [150]. SAMHD1 consists of a SAM domain responsible for 
protein-protein interaction and a HD domain with nucleotide phosphohydrolase 
activity. Vpx binds SAMHD1 and brings it to an ubiquitin ligase complex for 
ubiquitination and subsequent degradation. Restriction of SAMHD1 is related to the 
hydrolysis of intracellular deoxynucleoside triphosphates (dNTPs), thus lowering 
their concentration to below those required for a functional synthesis of viral DNA. 
[151]. 
SAMHD1 may play an additional role in limiting innate immune signaling to HIV 
replication, especially in DCs. Indeed, DCs rendered permissive to HIV-1 infection 
through the expression of Vpx, which causes SAMHD1 degradation, induces type-I 
IFNs[152]. Thus, HIV-1 seems to avoid infecting DCs as they do not induce IFNs, 
but stealthily passes through DCs to facilitate its infection of helper T cells. 
Consistent with an inhibitory effect of SAMHD1 on IFN induction, mutations in the 
SAMHD1 gene are associated with Aicardi-Goutières Syndrome (AGS) [153], an 
autoimmune disease characterized by elevated levels of IFNα. 
Interestingly, another AGS-associated gene, TREX1, has been shown to be 
important for HIV replication, specifically innate immune responses to HIV DNA 
[137]. TREX1 is a 3' exonuclease that contains conserved exonuclease N-terminal 
motifs and a C-terminal hydrophobic region important for its localization to the 
cytoplasm and endoplasmic reticulum (ER). TREX1 bound to cytosolic HIV DNA 
and digested excess non-productive HIV DNA that would otherwise activate 
interferon expression via a pathway dependent on the kinase TBK1, the adaptor 
STING and the transcription factor IRF3 [137]. TREX1 also prevents autoimmunity 
induced by DNA derived from endogenous retroelements [154], which may explain 
the AGS disease in patients carrying loss of function mutations of TREX1. 
Although both SAMHD1 and TREX1 are related to the same autoimmune disease, 
they show opposite effects on HIV-1 replication. SAMHD1 is antiviral whereas 
TREX1 is proviral for HIV-1, through distinct mechanisms. Interestingly, both 
proteins seems to target the reverse transcription step, by limiting the dNTP supply 
(SAMHD1) or by inhibiting immune recognition of non-productive RT products 
(TREX1). Taken together, HIV reverse transcription is becoming an increasingly 
important process in the HIV life cycle that is carefully regulated by a concerted 
effort of viral and host factors.  
2.3.2.4.5 IFN-induced myxovirus resistance 2 (MX2) 
Human dynamin-like IFN-induced myxovirus resistance 2 (MX2, also known as 
MXB) is a member of the IFN-inducible guanosine triphosphatase (GTPase) 
superfamily that includes proteins involved in several cellular processas well as in 
resistance to intracellular pathogens [155]. To date, relatively little informations 
about MX2 role and function are available. Recently, a group of researchers has 
described MX2 protein as a strong inhibitor of HIV-1 infection and as a key effector 
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of IFN-α-mediated resistance to HIV-1 infection [156]. In this study, the ability of 
MX2 to suppress infection have been confirmed in presence of different strains of 
HIV-1 and, similarly, on divergent simian immunodeficiency viruses. In contrast, no 
effect was shown on other retrovirusessuch as murine leukaemia virus. Thus, 
susceptibility to MX2 protein is dictated by  the capsid region of viral Gag protein, 
and the block to infection occurs at a late post-entry step causing  the suppression 
of nuclear accumulation and chromosomal integration of nascent viral 
complementary DNA.. Interesting, human MX1, closely related protein that has 
long been recognized as a broadly acting inhibitor of RNA and DNA viruses, 
including the orthomyxovirus influenza A virus [157, 158], does not affect HIV-1, 
whereas MX2 is ineffective against influenza virus. Thus, MX2 anti-HIV-1 
resistance factor may represent a new therapeutic approach for the treatment of 
HIV-1 infection. 
2.3.2.4.6 Antiviral role of 25-hydroxycholesterol (25-HC) 
Cholesterol is an essential component of cellular membranes and its biosynthetic 
pathway must be tightly regulated. The sterol regulatory element–binding protein 
(SREBP) family members provide a feedback regulatory system involved in 
biosynthesis and uptake of cholesterol preferentially by SREBP2 [159]. The liver X 
receptor (LXR) family members, instead, are involved in the elimination of excess 
cholesterol [160]. Additionally, SREBP1 and LXR transcription factors also work 
together to integrate cholesterol homeostasis with fatty-acid metabolism [161, 162].  
LXR family consists of two members LXR, and LXR, that regulate, as 
heterodimers with retinoid X receptors (RXRs), the expression of target gene by 
binding to LXR-response elements (LRE) on their promoters [163]. In the absence 
of activating ligands, LXR-RXR heterodimers interact with corepressor complexes 
that actively repress gene expression. LXRs positively regulate the expression of 
genes encoding lipid-transport proteins, such as ATP-binding cassette A1 
(ABCA1), ATP-binding cassette G1 (ABCG1), apolipoprotein E (ApoE) and several 
enzymes involved in fatty-acid remodeling [164-166]. In contrast, LXRs negatively 
regulate gene expression of NF-B and AP-1 [167, 168].  
Sensing cellular cholesterol content is a key element for the regulation of 
intracellular cholesterol homeostasis. Once SREBP-cleavage activating protein 
(SCAP) senses low cholesterol levels in the ER, dissociates from ER-retention 
protein INSIG1 and INSIG2, and permits the proteolytically cleavage of SREBP 
releasing the active N-terminal transcription factor [162]. This is then delivered to 
the nucleus where it binds to sterol-regulatory element (SREs) in the promoter of 
target genes. By contrast, in presence of high cholesterol levels, SREBP 
precursors are sequestered in the ER. The activities of LXR and SREBP pathway 
are finely regulated by cholesterol precursors and oxysterols [162] (fig. 18).  
The connection between virus and cholesterol has been widely established in the 
last few years. Many viral pathogens indeed exploit cellular lipid metabolism to 
ensure a correct amount of cholesterol for the release of functional virions [169].  
According to this observation, studies have provided evidence that activation of 
LXRs and/or inhibition of SREBP pathways results in the inhibition of viruses 
replication, including HIV and HCV [169-174]. Moreover, increased level of the ER-
associated enzyme cholesterol-25-hydroxylase (CH25H), responsible for the 
production of 25-hydroxycolesterol (25-HC), has been related to TLR stimulation 
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and IFNs. [175, 176]. Notably, distinct from known IFN-mediated antiviral 
mechanism, CH25H was recently found to inhibits growth of a wide range of 
enveloped viruses by production of a soluble oxysterols, 25-HC [177, 178]. 
Independent of its known regulatory effect on metabolism, 25-HC impairs virus-cell 
fusion by inducing cellular membrane changes. In particular, HIV induce a switch of 
cholesterol trafficking from physiological efflux to virus-controlled transport, thus 
reducing the ability of a cell to export excessive cholesterol. Intracellular cholesterol 
metabolism control is essential for the correct assembly and release of functional 
virions. 
 
 
 
 
Figure 18 – Regulation of cellular cholesterol homeostasis [Spann N.J. Nat Imm., 2013] 
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The amplitude of the spectrum of pathogens targeted by thiazolides makes it very 
unlikely that the action of these compounds is mediated by a pathogen-specific 
mechanism(s), suggesting instead that thiazolides act as immunomodulants. The 
potential effect of these compounds on immune responses has nevertheless not 
been investigated so far. In particular, as innate immunity and type 1 IFNs are 
pivotal in early and potent antiviral immune responses not antigen-restricted, it is 
plausible to hypothesize that thiazolides could potentiate this arm of the immune 
response. To verify this possibility, we performed extensive in vitro analyses on the 
immunomodulatory effects of two generations of thiazolides, TIZ and RM4848 a 
second generation non-nitro thiazolide, using two different viral models: Influenza 
and HIV-1. In particular, the aim of this study was to evaluate thiazolide effects on 
TLR and type I IFNs expression key protein involved in viral recognition and innate 
immune responses against viruses.  
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1. SAMPLE COLLECTION AND DRUGS PREPARATION 
1.1. Thiazolides  
TIZ and the second generation thiazolides RM4848 were provided by Romark 
Laboratories (Tampa, Florida). Powders were resuspended in dimethyilsulfoxide 
(DMSO, Sigma Aldrich, St. Louis, MO, USA) to obtain a 40 g/ml solution and 
stored at 2-8°C until use. 
1.2. Blood sample collection and PBMCs separation 
Whole blood was collected from 20 healthy blood donors by venipuncture in 
Vacutainer tubes containing ethylenediaminetetraacetic acid (EDTA, Becton 
Dickinson, Rutherford, NJ, USA) following informed consent. Samples were 
centrifuged at 1400 rpm for 10 minutes and plasma was collected and stored at -20 
for subsequent analysis. The remaining sample, composed by erythrocytes, 
peripheral blood mononuclear cells (PBMCs), granulocytes and platelets, was 
diluted in phosphate buffered saline (PBS, PBI International, Milano, Italy) and 
separated on a lymphocytes separation medium (Lympholyte-H, Cederlane 
Laboratories, Burlington, NC, USA) for 25 minutes at 2300 rpm. PBMCs layer were 
carefully removed and washed twice in PBS (PBI, Milan, Italy) and cell number and 
cellular vitality were determined. 
1.3. Cell count 
Cell count was performed with the automated cell counter ADAM-MC (Digital Bio, 
NanoEnTek Inc, Corea). ADAM-MC automatic cell counter measures total cell 
numbers and cell viabilities by cutting edge detection technologies. Instead of 
tryphan blue staining, which can lead to inaccurate data, ADAM-MC utilizes two 
sensitive fluorescence dye staining solutions, AccuStain Solution T (Propidium 
Iodide/lysis solution) and AccuStain Solution N (Propidium IodideI/PBS). AccuStain 
Solution T allows plasma membrane disruption and nucleus staining for 
measurement of total cell concentration. AccuStain Solution N allows staining of 
non-viable cells, thus leaving viable cells completely intact. A 532 nm optic laser is 
automatically focused onto the cell solution inserted into a disposable microchip 
and cell analysis is made by a CCD detection technology. 
1.4. MTT assay 
Toxicity of thiazolides was determined by a MTT based assay (Sigma Aldrich, St. 
Louis, MO, USA). The MTT system is a method to measure the activity of living 
cells via mitochondrial dehydrogenases activity. Viable cells reduce the yellow 
tetrazolium salt 1-(4,5-dimethylthiazol-2-yl)-3,5diphenyl formazan (MTT) to purple 
formazan insoluble crystals. 
Cells were cultured in RPMI medium (Euroclone, Milan, Italy) supplemented with 
20% FBS (Euroclone, Milan, Italy), penicillin and streptomycin, L-glutamine and 
gentamycin (Euroclone, Milan, Italy) alone or in presence of increasing 
concentration (0.5 µg/ml, 1 µg/ml, 10 µg/ml, 20 µg/ml and 200 µg/ml) of drugs, 
diluted in medium culture for 1, 3, 5, 7 and 10 days. Every two days the 50% of 
medium was removed and replaced with fresh medium containing drugs at the 
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corresponding concentrations. After culturing, cells were washed five times in 
RPMI without phenol red (Euroclone, Milan, Italy). PBMCs were then incubated in 
medium RPMI without phenol red plus 10% FBS containing MTT (500 µg/ml) for a 
period of 4 hours. Insoluble formazan product was dissolved by incubation with an 
amount of an acidified Solubilisation Solution (Sigma Aldrich, St. Louis, MO, USA) 
equal to original culture media volume. Finally formazan absorbance were 
measured at 595 nm with IMark microplate reader (Biorad, Hercules, CA, USA). 
PBMCs viability were established by dividing the absorbance reading of the 
formazan by the dry weight of cell cultures. Toxicity were determined by dividing 
viability of the drug- treated cells by viability of untreated cell control. 
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2. INFLUENZA VIRUS ANALYSIS 
2.1. Influenza Virus (FLU) strains 
The influenza virus (FLU) used is live UV-inactivated influenza virus 
(A/Bangkok/RX73 and A/Puerto Rico/8/34 strains; 1:800) and the 1998–1999 
formula of influenza virus vaccine (1:5000; Wyeth Laboratories Inc., Marietta, PA, 
USA). The influenza virus vaccine is an inactivated trivalent subunit formulation 
that contains the hemagglutinin antigens of influenza A H1N1, influenza A H1N3, 
and influenza B virus strains (each at 30 mg/ml). Viruses were kindly provided by 
Dr. Shearer, National Institutes of Health (NIH, Bethesda, Washington, USA). 
2.2. PBMCs stimulation with thiazolides in presence of FLU antigens 
PBMC re-suspended at 4x10
6
/ml in RPMI 1640 (Euroclone, Milan, Italy) were 
incubated for 4 hours with two different doses of TIZ or RM4848 (1 or 10 µg/ml) 
(Romark Laboratories, L.C. Tampa, Florida) in presence/absence of FLU antigens 
(final dilution 1:400, National Institutes of Health, Bethesda, MD, USA). Anti-CD28 
mAb (R&D Systems, Minneapolis, MN, USA) was added during incubation 
(1mg/well) to facilitate co-stimulation. For cytokine analyses, 10 µg/ml Brefeldin A 
(Sigma-Aldrich, St. Louis, MO, USA) was added to cell cultures during the last 18 
hours to block protein secretion.  
2.3. Comparison between TIZ or IFNα treatment in FLU-stimulated and 
unstimulated PBMCs 
PBMCs stimulated with FLU antigens were re-suspended at 4x10
6
/ml in complete 
medium and incubated for 4 hours with TIZ (10 µg/ml) (Romark Laboratories, L.C. 
Tampa, Florida) or IFNα (final diluition 1:400 IU/ml) (Sigma Aldrich, St. Louis, MO, 
USA). PBMCs not stimulated with FLU in the same conditions were used as 
control. Anti-CD28 mAb (R&D Systems, Minneapolis, MN, USA) was added during 
incubation (1mg/well) to facilitate co-stimulation. For cytokine analyses, 10 µg/ml 
Brefeldin A (Sigma-Aldrich, St. Louis, MO, USA) was added to cell cultures during 
the last 18 hours to block protein secretion.  
2.4. Flow cytometry analysis 
All flow cytometry analysis were performed using a CYTOMICS FC-500 flow 
cytometer (Beckman-Coulter, Miami, FL, USA) equipped with a double 15-mV 
argon ion laser operating at 456 and 488, interfaced with CXP 21 software 
(Beckman-Coulter, Miami, FL, USA). For each analysis 20000 events will be 
acquired and gated on CD4, CD8 or CD14 expression and side scatter properties. 
Green fluorescence from FITC was collected through a 525 nm band pass filter 
(FL1), orange-red fluorescence from PE was collected through a 575 nm band 
pass filter (FL2), red fluorescence from 7-AAD was collected through a 620 nm 
band pass (FL-3), red fluorescence from PE- Cy5 was collected through a 670 nm 
band pass filter (FL4), deep red fluorescence from PE- Cy7 was collected through 
a 755 nm band pass filter (FL-5). Data were collected using linear amplifiers for 
forward and side scatter and logarithmic amplifiers for FL-1, FL-2, FL-3, FL-4 and 
FL-5. 
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2.4.1. TLRs expression on monocytes 
After stimulation, PBMCs were resuspended in PBS and stained for surface mAb 
CD14PECY5 (Beckman-Coulter, Fullerton, CA, USA). After a 15-minute incubation 
at room temperature in the dark, cells were washed and fixed in 1% 
paraformaldehyde in PBS. Cells were then permeabilizated with saponin 0,5% 
(Sigma-Aldrich, St. Louis, MO, USA) and monoclonal antibodies for TLR3 PE 
(eBioscience, San Diego, CA, USA) and TLR8 FITC (Imgenex Corporation, San 
Diego, CA, USA) or TLR7 FITC (R&D Systems, Minneapolis, MN, USA) were 
added. Cells were incubated for 45 minutes at 4°C in the dark, washed and fixed in 
1% paraformaldehyde in PBS. 
2.4.2. Percentage of IFNα-secreting pDC 
PBMCs, stimulated with TIZ or IFNα and resuspended in PBS were stained for 
surface mAb CD123 PECy7, LIN
-
 PECy5 (CD8, CD4, CD19, CD14) and HLA-DRII 
PE (Beckman-Coulter, Fullerton, CA, USA). After a 15-minute incubation at room 
temperature in the dark, cells were washed and fixed in 1% paraformaldehyde in 
PBS. Cells were then permeabilizated with saponin 0,5% (Sigma-Aldrich, St. Louis, 
MO, USA) and monoclonal antibodies for IFNα FITC (eBioscience, San Diego, CA, 
USA) were added. Cells were incubated for 45 minutes at 4°C in the dark, washed 
and fixed in 1% paraformaldehyde in PBS. 
2.4.3. Intracellular cytokines expression 
After stimulation, PBMC were washed in PBS and stained for CD4 PECy5, CD8 
PECy7 or CD14PECy5 (Beckman-coulter, Fullerton, CA, USA) for 15 min at RT in 
the dark. PBMCs will be fixed in 1% paraformaldehyde (Sigma-Aldrich, St. Louis, 
MO, USA) 15 min at 4°C and then washed. Cells were then re-suspended in 0,5% 
Saponin (Sigma-Aldrich, St. Louis, MO, USA) and stained for IL2 PE and IFN 
FITC (Beckman-Coulter, Fullerton, CA, USA). After a 45 minutes incubation at 4°C 
in the dark, cells will be washed and fixed in 1% paraformaldehyde in PBS.  
2.4.4. Statistical analysis 
Comparisons between groups were analyzed to evaluate immunological 
differences. Kruskal & Wallis analysis of variance was performed for each variable; 
Bonferroni correction was applied to the results. Two-sided p-values were 
considered. Data analysis was performed using the SPSS statistical package 
(SPSS Inc. Chicago, Illinois, USA). 
2.5. RNA extraction and Real Time PCR 
RNA was extracted from cultured PBMCs by using the acid guanidium 
thiocyanate–phenol–chloroform method. RNAzol B reagent (Duotech, Milan, Italy), 
a monophase solution containing phenol and guanidine thiocyanate, was used. 
PBMCs were lysed in RNAzol B and the lysate were separated into aqueous and 
organic phase by the addition of chloroform (20% of RNAzol B initial volume used). 
Samples were centrifuged (at 12,000g 15 minutes at 4°C) to efficiently remove 
DNA and proteins from the aqueous phase containing RNA. The pure, not 
degraded, RNA is obtained from the aqueous phase by the isopropanol 
precipitation and washing with 75% ethanol.  
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2.5.1. DNAse treatment and retrotranscription (RT) 
RNA was dissolved in RNase-free water, and purified from genomic DNA with 
TURBO DNAse (Applied Biosystems/Ambion, Austin, TX, USA), a genetically 
engineered form of bovine DNase I with greater catalytic efficiency than 
conventional DNase I at higher salt concentrations and lower DNA concentrations. 
A reaction mixture, containing 1µg of RNA, Turbo DNasi 1U and TURBO DNasi 
Buffer, were incubated 30 minutes at 37 °C. Then DNase was inactivated by 
DNase inactivation reagent (Applied Biosystems/Ambion, Austin, TX, USA), that 
binds and removes the divalent cations from DNase. 1 µg of RNA was reverse 
transcribed into first-strand cDNA in a 20-µl final volume. A reaction mixture,  
containing 1 µM random hexanucleotide primers, 1 µM oligo dT and the RNA,  was 
heated at 70 °C for 5 minutes to melt secondary structure within the template. The 
mixture was immediately cooled on ice to prevent secondary structure from 
reforming. A dNTPs mix, 200 U Moloney murine leukemia virus reverse 
transcriptase (M-MLV RT), 20 U Recombinant RNasi inhibitor and M-MLV 5X 
reaction buffer were added (Promega, Fitchburg, WI, USA). The reaction mix were 
incubated 60 minutes at 42 °C and then heated 5 minutes at 95 °C to inactivate the 
RT.  
2.5.2. Real time PCR  
cDNA quantification of genes involved in this study was performed by real-time 
PCR (DNA Engine Opticon 2; MJ Research, Ramsey, MN). Reactions were 
performed using a SYBR Green PCR mix (Promega, Fitchburg, WI, USA). SYBR 
green is a fluorogenic minor groove binding dye that exhibits little fluorescence 
when in solution but emits a strong fluorescent signal upon binding to double-
stranded DNA. Reactions were performed according with the following thermal 
profile: an initial denaturation (95 °C ,15 minutes) followed by 40 cycles of 15 sec 
at 95 °C (denaturation) and 1 min at 60 °C (annealing) and 20 seconds at 72 °C 
(extension). By recording the amount of fluorescence emission at each cycle, the 
PCR reaction was monitored during exponential phase, where the first significant 
increase in the amount of PCR product correlates to the initial amount of target 
template. The higher the starting copy number of the nucleic acid target, the sooner 
a significant increase in fluorescence is observed. Melting point or dissociation 
curve analysis for amplicon identification, was performed. 
The threshold line is the level of the detection or the point at which a reaction the 
reaction reaches a fluorescent intensity above background (the mean of 
fluorescence values detected from to third to tenth cycle, when target amplification 
it is no appreciable yet). The threshold was set placed above baseline activity and 
in the exponential increase phase of the amplification for the most accurate 
reading. The parameter Ct (Threshold cycle) is defined as the fractional cycle 
number at which the fluorescence passes the fixed threshold. The higher the initial 
amount of genomic DNA, the sooner accumulated product is detected in the PCR 
process, and the lower the Ct value. A Ct value of 40 or higher means no 
amplification and this value was not  included in the calculations.  
Results were expressed as ΔΔCt and presented as ratios between the target gene 
and the GAPDH housekeeping mRNA. All the samples were analyzed in triplicate. 
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2.5.3. Real Time PCR Arrays 
2.5.3.1. Human Toll-like Receptors signaling pathway 
TLR signalling pathways were analysed in a PCR array including a set of optimized 
real-time PCR primer assays on 96-well plates (SABiosciences Corporation, 
Frederick, MD, USA). This approach permits the monitoring of mRNA expression of 
84 genes (tab. 4) related to the TLR pathway, plus five housekeeping genes, 
following the procedures suggested by the manufacturer. Controls were also 
included on each array for genomic DNA contamination, RNA quality, and general 
PCR performance. The results were analysed by SABioscences online software. 
Only targets showing at least a 2-fold modulation were considered significative.  
The experiments have been run on all of the subjects included in the study pooled 
into distinct groups on the basis of the treatment (no drugs, TIZ or RM4848). Thus, 
results represent the mean value of the different targets analysed in each group. 
Furthermore, those targets showing marked differences between groups have 
been confirmed by Real time PCR on each individual member of the sample 
confirming the data obtained in the array. 
 
 
 
Table 4 – Complete list of TLR pathway genes analyzed (SABiosciences) 
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2.5.3.2. Human Type I IFN response 
Type I IFNs signalling pathways were analysed in a PCR array (SABiosciences 
Corporation, Frederick, MD, USA) (see Human TLRs signaling for details) (tab. 5). 
 
 
 
Table 5 – Complete list of Type I IFN pathway genes analyzed (SABiosciences) 
2.6. Clinical trial design  
Six hundred and twenty four (624) patients were enrolled at 74 outpatient study 
centers throughout the United States. Eligibility criteria include age 12-65 years, 
oral temperature ≥ 100.4º F, at least one respiratory symptom and one 
constitutional symptom, symptom onset ≤48 hours of enrolment, laboratory 
confirmed influenza in the community, not at risk of influenza complications based 
on CDC criteria. Patients were randomized to receive NTZ: 600 mg, NTZ: 300 mg 
or Placebo twice daily for 5 days and were followed for 28 days. Symptoms were 
graded (0 to 3, absent to severe) and recorded twice daily in a patient diary. 
Nasopharyngeal swabs collected at baseline and day 7 for all patients and on days 
2, 3, 4 and 5 for a subset of patients subjected to PCR and culture to identify and 
quantify viruses. The primary endpoint was time to alleviation of symptoms (all 
symptoms absent or mild). The study protocol was approved by a central Ethical 
Committee and the study was carried out under the Food and Drug Administration 
IND No 107.316.  
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3. HUMAN IMMUNODEFICIENCY VIRUS 1 
3.1. HIV-1 strains  
The laboratory-adapted HIV-1 strains used in the experiments was the R5 tropic 
HIV-1BaL (contributed by Drs. S. Gartner, M. Popovic and R. Gallo, courtesy of the 
National Institutes of Health AIDS Research and Reference Reagent Program).  
The virus were provided through the EU programme EVA centre for AIDS 
Reagents (The National Institute for Biological Standards and Control NIBSC, 
Potter Bars, UK).  
3.1.1. HIV-1BaL expansion in CCR5
+ JURKAT T cells  
The HIV-1BaL was grown to high titer in CCR5
+ 
Jurkat T cells, stably expressing 
CCR5. Cells were maintained in a logarithmic phase of growth for 2 to 3 days 
before infection, at the concentration between 0.1 to 0.5x10
6 
cells/ml in complete 
medium. Cells were seeded at density of 2×10
6
 cells/ml and were incubated with 
HIV-1Bal for 3 hours at 37°C. After infection cells were washed and maintained in 
culture at density of 1x10
6 
cells/ml in complete RPMI medium for 21 days. Two 
times per week the 50% of medium and of the cells was removed and replaced 
with fresh RPMI medium. Supernatants were collected, aliquoted and stored in 
liquid nitrogen. Viral concentration in supernatants was monitored by p24 ELISA 
(PerkinElmer, Waltham, MA, USA). HIV-1BaL concentration in supernatants 21 days 
after infection was 617ng/ml. 
3.2. HIV-1BaL infection assay  
Whole blood was collected from 20 healthy volunteers by venupuncture in 
Vacutainer tubes containing EDTA (Becton Dickinson, NJ, USA), and PBMC were 
separated on lymphocyte separation medium (Organon Teknica, Malvern, PA, 
USA). PBMCs (10×106 cells/mL) were resuspended in medium containing 
1ng/1x10
6
 cells of HIV-1BaL p24 viral input and incubated for 24 hours at 37°C and 
5% Co2. Cells were then washed and resuspended in complete medium with 
interleukin-2 (IL-2,15 ng/mL) (Sigma-Aldrich, St. Louis, MO, USA), 
phytohemagglutinin (PHA, 7.5 μg/mL) (Sigma-Aldrich, St. Louis, MO, USA) and TIZ 
(10 μg/mL) or RM4848 (10µg/ml) or TO901317 (LXR agonist, 1 µM) (Sigma-
Aldrich, St. Louis, MO, USA) for 3 days. After viability assessment cells were 
washed and resuspended in RPMI complete medium added with IL2 and TIZ or 
RM4848 or TO901317 at the same concentrations. Cells were then plated in non-
treated 24-well tissue culture plates and incubated at 37°C and 5% CO2. After 
other 4 days (7 days post infection), 1 x 10
6
 PBMC were collected for gene 
expression analyses whereas 2.5 x 10
5
 cells for each condition for protein 
expression analysis. Supernatants were collected and stored at -20°C for 
subsequent analysis. After 7 days (day 10 post infection ) supernatants were 
collected for batched ELISA of p24 antigen. Absolute levels of p24 were measured 
using the Alliance HIV-1 p24 ELISA Kit (PerkinElmer, Waltham, MA, USA). 1 x 10
6
 
PBMC were collected for gene expression analyses whereas 2.5 x 10
5
 cells for 
each condition for protein expression analysis. Every maximum 3 days half 
medium was changed with fresh one. 
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The RM4848 action and kinetic were evaluated during the HIV-1BaL infection assay 
by adding the compound to cell cultures at different time-points. In particular, 
PBMCs were treated with RM4848 for two days before infection, during infection, 
for 10 days post infection, or for all the experiment. Untreated condition was used 
as control. Supernatants were collected and stored at -20°C for subsequent 
analysis.  
3.3. Flow cytometry analysis 
All flow cytometric analyses were performed using a CYTOMICS FC-500 flow 
cytometer (Beckman-Coulter, Miami, FL, USA). See 2.4 paragraph for details about 
the method. 
3.3.1. Identification of apoptosis by 7-amino actinomycin D (7AAD) 
To evaluate the toxicity of thiazolides cells were incubated with different 
concentrations of drugs for 1, 4 or 7 days. After the incubation cells were stained 
with DNA incorporating dye 7-aminoactinomicyn D (7-AAD, Beckman-coulter, 
Fullerton, CA, USA) for 15 minutes at room temperature in the dark. After, 500µl of 
PBS were added and samples were analyzed by flow cytometry.  
Scattergrams were generated by combining forward light scatter with 7AAD 
fluorescence, and regions were drawn around clear-cut populations having 
negative, dim, and bright fluorescence. 
3.3.2. Intracellular cytokines expression 
After stimulation, PBMC were washed in PBS and stained for CD4PC5, CD8PC7 
or CD14PC5 (Beckman-coulter, Fullerton, CA, USA) for 15 min at RT in the dark. 
PBMCs were fixed in 1% paraformaldehyde (Sigma-Aldrich, St. Louis, MO, USA) 
15 min at 4°C and then washed. Cells will be then re-suspended in 0,5% Saponin 
(Sigma-Aldrich, St. Louis, MO, USA) and stained for IL2 PE, IFN FITC (Beckman 
Coulter). After a 45 minutes incubation at 4°C in the dark, cells will be washed and 
fixed in 1% paraformaldehyde in PBS.  
3.4. ELISA assay 
3.4.1. p24 ELISA 
Culture supernatants were collected at day 7 and day 10 after HIV-1Bal infection 
assay. p24 concentration, as a measure of HIV infection, was assayed using the 
Alliance HIV-1 p24 Antigen kit (Perkin Elmer, Boston, USA) following 
manufacturer’s instructions. Microplate wells are already pre-coated with a 
monoclonal antibody endowed with a high specificity and affinity to HIV-1 p24. 
Standards and samples (when needed) were diluted in inoculated culture medium. 
A five point standard curve using two-fold serial dilution and an high standard of 
100 pg/ml were prepared. A linear standard curve was generated. Firstly Triton X-
100 was added to all microplate wells (except substrate blank) to disaggregate 
HIV-1 virion, then the standards and samples were added to designated wells and 
the plate were incubated 2 hours at 37 °C. Plate were washed with wash buffer 
(phosphate buffer plus 1% Tween-20). Biotinylated polyclonal antibody to HIV-1 
p24 was added to all wells except substrate blank at 37 °C for 1 hours. After 
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washes streptavidine conjugated with the horseradish peroxidase was added and 
the microplate was incubated 30 minutes at room temperature (RT). After washing 
the chromogenic substrate ortho-phenilenediamine-HCL (OPD) were added 30 
minutes to all wells at RT. Following incubation with OPD, yellow color directly 
proportional to amount of p24 captured was generated. Reaction was stopped by 
adding stop solution (4N sulfuric acid) to all wells. Plates were immediately read at 
490 nm, with the correction wavelength set at 655 nm, using the IMark microplate 
reader equipped with Microplate Manager® 6 software (both from Biorad, 
Hercules, CA, USA). 
3.4.2. Multiplex Immunoassay 
3.4.2.1. Measurement of Cytokine Concentrations by Multiplex Immunoassay 
and ELISA Immunoassay 
Cytokines concentrations were determined using multiplex sandwich 
immunoassays with the Fluorokine Multi Analyte Profiling Kit (R&D Systems, 
Minneapolis, MN, USA) according to manufacturer's protocol. The following 
cytokines were included in the kit: IL2, IFN, MCP-1, MIP1, MIP1 and RANTES. 
Cytokines concentrations were calculated using a standard curve derived from the 
reference cytokine concentration standards supplied by the manufacturer. 
3.4.2.2. Statistical analysis  
Wilcoxon Rank Sum tests were used to evaluate differences in p24 levels, cytokine 
expression and cell counts. All tests were two-tailed and were performed in R 
(http://cran.r-project.org/). 
3.5. RNA extraction, retrotranscription (RT) and Real Time PCR 
See paragraph 2.5. for details about the methods. 
3.5.3. Real Time PCR Arrays 
3.5.3.1. Human Toll-like Receptors signaling pathway 
TLR signalling pathways were analysed in a PCR array including a set of optimized 
real-time PCR primer assays on 96-well plates (SABiosciences Corporation, 
Frederick, MD, USA). See paragraph 2.5.3.1 for details about the methods. 
3.5.3.2. Human Type I IFN response 
Type I IFNs signalling pathways were analysed in a PCR array (SABiosciences 
Corporation, Frederick, MD, USA). See paragraph 2.5.3.2 for details about the 
methods. 
3.5.3.3. HIV-1 human response 
Type I IFNs signalling pathways were analysed in a PCR array (SABiosciences 
Corporation, Frederick, MD, USA) (tab. 6). See paragraph 2.5.3.1 for details about 
the methods. 
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Table 6 – Complete list of  HIV-1 human response pathway genes (SABiosciences) 
  
RESULTS AND DISCUSSION 
Results and Discussion 
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1. THIAZOLIDES 
1.1. Evaluation of thiazolide toxicity 
The colorimetric tetrazolium salt (MTT) assay, that monitors metabolic activity of 
cultured cells, was adapted to analyse the viability of cells exposed to thiazolides. 
After having established a suitable cell seeding density, PBMC isolated from 5 
healthy controls were treated with different doses of TIZ or RM4848 (1, 5, 10, 20 
and 100 µg/ml) at different time-points (1, 3, 5 and 10 days) to test the dose-
dependence and the time-course of PBMC viability reduction (fig. 19). The higher 
dose (100 µg/ml) of thiazolides reduced cell viability after 3 or more days of drug 
exposure. The most severe effect was observed 10 days after treatment with MTT 
reduction of 35% for TIZ and 86% for RM4848 compared to drug-untreated cells. 
Results obtained demonstrated that concentrations lower than 20 µg/ml were 
sufficient to maintain pharmacological properties without affecting cell viability. 
 
 
 
Figure 19 – Percentage of PBMC viability after culture with different doses of TIZ (1, 5, 10, 
20 and 100 µg/ml) (A) or RM4848 (1, 5, 10, 20 and 100 µg/ml) (B) at different time-points (1, 
3, 5 and 10 days) assessed by MTT assay. 
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2. INFLUENZA VIRUS MODEL  
2.1. Thiazolides enhance TLR7 and TLR8 expression on immune cells  
Early antiviral response requires TLR activation induced by ligation with pathogen-
associated molecular patterns (PAMPs). In particular TLR3, TLR7 and TLR8 
recognize nucleic acids produced during viral replication. We examined whether 
TLR expression could be modulated by two different doses of TIZ or RM4848 (1 
and 10 µg/ml). To this purpose, TLR3, TLR7 and TLR8 expression was evaluated 
on CD14
+ 
cells (monocytes) both in unstimulated conditions and after FLU-
stimulation. Results showed that, whereas thiazolides did not influence TLR3 
expression (data not shown), TLR7 and TLR8 were up-regulated in a dose 
dependent manner on the surface of FLU-stimulated CD14
+
 cells, achieving 
statistical significance only in the presence of the higher dose of drugs (fig. 20). A 
similar trend was observed in unstimulated conditions in the presence of 
thiazolides but without reaching statistical significance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20 - Mean fluorescence intensity (mfi) of TLR7- and TLR8- expressing CD14+ cells 
in unstimulated and FLU-stimulated conditions and in the absence or in the presence of two 
different doses of TIZ (1.0 µg/ml; 10 µg/ml) (A) or RM4848 (1.0 µg/ml; 10 µg/ml) (B). Mean 
values ± S.D. and p values are indicated. 
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Activation of TLR7 and TLR8 triggers inflammatory responses characterized by 
type I IFN production in virus-infected cells via activation of downstream NF-B and 
type I IFN promoters. Thus, modulation of TLRs expression by thiazolides seems 
to be the first key element for activation of innate immune response against 
viruses.  
2.2. Thiazolides upregulates gene expression of molecules involved in 
TLR pathway  
As thiazolides upregulate TLR7 and TLR8 expression, we next evaluated the 
possible effects of these compounds on genes involved in the TLR-associated 
transduction pathway using a real-time PCR array.  
4 hour-TIZ incubation in unstimulated condition resulted in the upregulation of 
TLR3, TLR7, TLR8, TLR9 expression, along with the increase of downstream 
molecules such as the adaptor protein TICAM2, the interferon regulatory factor 
TBK1 and the effectors NR2C2 and UBE2V1. Moreover, as a consequence of TLR 
activation, an augmented mRNA expression of IFN1, IFN1, CSF3 and IL6 
(genes involved in cytokine-mediated signaling), and IL12A and IL2 (key regulators 
of adaptive immunity) was observed as well (fig. 21A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21 – mRNA expression of genes involved in TLR signaling after TIZ (10g/ml) (A) or 
RM4848 (10g/ml) (B) treatment in unstimulated condition.  
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In unstimulated cells, incubation with RM4848 (10 µg/ml) significantly upregulated: 
TLR3, TLR4, TLR7, TLR8, IFN1, IFN1, and IFN, different downstream and 
target genes (IL6, IL1A, IL1B, CCL2, IL8, JUN, IRAK1, IRAK2) and a regulator of 
adaptative immunity (CD80) compared to the untreated condition (fig. 21B).  
Upon FLU-stimulation, thiazolide effect on TLR pathway resulted in a more evident 
gene expression modulation. In particular, TIZ treatment was associated with the 
upregulation of TLR7, TLR8, and TLR9, different downstream and target genes 
(CSF3, CXCL10, IL6, MAP3K1, NFKB2, NFKBIL1, NR2C2, SIGIRR, TBK1), some 
regulators of adaptative immunity (IL12A, IL2, CD80), specific adaptors (HRAS, 
MAPK8IP3, MyD88, TICAM2, TIRAP), and the effector molecule EIF2AK2 mRNA 
expression which in turn inhibits protein synthesis. As a consequence of TLR 
pathway activation, a consistent upregulation of IFNs (IFNα1, IFNβ1, IFN) was 
reported as well (fig. 22A).  
RM4848 (10 µg/ml) treatment in FLU-stimulated cells showed an increased mRNA 
expression of TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, and TLR10, 
downstream pathway genes (IL6, JUN, NFKB2), regulators of adaptative immunity 
(CD80, IL12A, IL2), effectors (UBE2V1, TRAF6), and IFNs (IFN1, IFN1, IFN) 
(fig. 22B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22 – mRNA expression of genes involved in TLR signalling after TIZ (10 g/ml) (A) 
or RM4848 (10 g/ml) (B) treatment in FLU-stimulated condition. 
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2.3. Thiazolides increase IFNα-secreting plasmacytoid Dendritic Cells  
Dendritic cells (DCs) are specialized sentinels of the immune system that detect 
invading pathogens and play a crucial role in orchestrating immune responses. In 
particular, in response to viral infection, a specialized DC subset, plasmacytoid 
dendritic cells (pDC), produces high quantities of type I IFNs. Thus, IFN production 
is considered as a hallmark response underlying cellular antiviral immune 
responses. 
Since thiazolide treatment of FLU-stimulated PBMCs resulted in an increased 
expression of type I IFNs, we verified the effects of these compounds on pDCs 
activation. Although no significant effect was detected in unstimulated conditions, 
the percentage of IFNα-secreting pDC was significantly increased in the presence 
of the highest dose of TIZ (p-value=0.05) (fig. 23A) or RM4848 (p-value=0.05) (fig. 
23B) in FLU-stimulated cell cultures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23 - IFNα-secreting pDC (%) evaluated on total pDC in unstimulated and FLU-
stimulated conditions. Data obtained in the absence or in the presence of two different 
doses of TIZ (1.0 µg/ml; 10 µg/ml) (A) or RM4848 (1.0 µg/ml; 10 µg/ml) (B) are indicated. 
Mean values, S.E. and p values are shown.  
2.4. Induction of the type I IFN pathway in response to thiazolides 
Activation of TLRs results in a variety of cellular responses including production of 
IFNs, pro-inflammatory cytokines and effector cytokines that direct adaptive 
immune responses. We, therefore, performed a Real-time PCR array to determine 
whether induction of type I IFNs observed in the presence of thiazolides could 
influence the expression of ISGs. 
Results obtained in unstimulated PBMCs treated with TIZ (10 µg/ml) showed an 
increase of IFN1, IFN, IFN4, and IFN1, and of different ISGs expression 
(ADAR, CXCL10, GBP1, IFI27, IFI16, MX1, OAS1, OAS2) (fig. 24A). Similarly, 
incubation with RM4848 (10 µg/ml) resulted in the upregulation of IFN1, IFN2, 
IFN4, IFN1, and IFN, ISGs (IFI30, IRF5, IRF7, ISG15, SHB, STAT2), antigen 
presentation genes (HLA-A, HLA-B, HLA-DQA1) and genes involved in type I IFN 
pathway (VEGFA) (fig. 24B). 
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Figure 24 - mRNA expression of genes involved in type I IFN signaling after TIZ (10 g/ml) 
(A) or RM4848 (10 g/ml) (B) treatment in unstimulated condition.  
 
Data obtained in FLU-stimulated PBMCs following 3 hour-incubation with TIZ 
showed an increase of both type I and type II IFNs (INF1, IFNAR2, IFN1, IFN). 
Furthermore, the compound upregulated specific ISGs (IFI6, IFI27, IRF1, MX1), 
antigen presentation genes (TAP1, HLA-A, HLA-B), and other genes involved in 
type I IFN pathway (CD70, PRKCZ, PRKRA, TRAF3) (fig. 25A).  
Upregulation of type I and type II IFNs (INF1, INF2, INF4, IFN1, IFN), ISGs 
(CXCL10, IFI27, IFIT1, NRG1, OAS1, OAS2, SHB), antigen presentation genes 
(HLA-A, HLA-B), and of a gene involved in this pathway (CD70) was observed after 
RM4848 stimulation as well (fig. 25B).  
Notably, the increase of restricted HLA-class I antigen gene expression would 
suggest an indirect effect of thiazolides on the onset of antiviral acquired immune 
responses. 
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Figure 25 - mRNA expression of genes involved in type I IFN pathway following TIZ (10 
g/ml) (A) or RM4848 (10 g/ml) (B) treatment in FLU-stimulated condition 
2.5. Modulation of intracellular cytokine expression   
An efficient antiviral immune response, including immunity to FLU virus, requires 
activation of both innate and acquired immune responses. Thus, we verified 
whether thiazolides would increase production of cytokines involved in the 
elicitation of acquired immune responses by antigen-stimulated lymphocytes.  
IFN and IL2 production by CD4+ T cells was evaluated both in unstimulated 
condition or upon stimulation with FLU-specific antigens. Only in FLU-stimulated 
cells, results showed a statistically significant increase in IFN production in the 
presence of the highest dose of TIZ (p-value=0.03) and of both doses of RM4848 
(1 µg/ml: p-value=0.04; 10 µg/ml: p-value=0.05). A similar trend was observed for 
IL2 synthesis (TIZ 10 µg/ml p-value=0.03; RM4848 10µg/ml p-value=0.04), thus 
confirming an important role of these compounds in the induction of an effective 
antigen-specific adaptive immunity (fig. 26). 
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Figure 26 - Percentage of IFN- and IL2- secreting CD4+ T cells in unstimulated and FLU-
stimulated conditions. Data obtained in the absence or in the presence of two different 
doses of TIZ (1.0 µg/ml; 10 µg/ml) (A) or RM4848 (1.0 µg/ml; 10 µg/ml) (B) are indicated. 
Mean values, S.E. and p values are shown. 
2.6. Thiazolide efficacy compared to IFNα stimulation  
IFNα effects on immune system were extensively explored  and nowadays IFNα is 
used as a standard treatment in several pathologic conditions. Unfortunately IFNα 
use is accompanied by a wide variety of possible side effects that may hamper 
reaching and maintaining the dose needed for maximal therapeutic effect while 
their occurrence can outweigh clinical benefit of IFNα treatment. Since we 
previously demonstrated that thiazolides positively affected a wide range of genes 
involved in type I IFN pathway, we thus compared the immunomodulatory effects of 
TIZ to those exerted by IFNα in FLU-stimulated PBMCs. 
Following 4 hour-IFNα stimulation, we analysed genes involved in both TLR and 
type I IFN pathway. Results indeed showed an upregulation of a large number of 
genes (fig. 27) involved in the generation of both innate and acquired immune 
responses.  
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Figure 27 – mRNA expression of genes involved in TLR (A) and in type I IFN (B) pathway 
following IFNα treatment in FLU-stimulated cells.   
 
Although IFNα immunomodulation was greater than that observed following TIZ 
treatment, in terms of either number of upregulated genes or relative level of 
mRNA expression, the less intense effects of thiazolides (fig. 28) could be 
notwithstanding considered positive in an effort to reduce side effects that 
characterized IFNα treatment. 
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Figure 28 – Comparison between mRNA expression of genes involved in TLR (A) and type 
I IFN (B) pathway following IFNα or TIZ treatment in FLU-stimulated cells.  
2.7. Clinical trial for the treatment of uncomplicated influenza  
The results obtained in vitro, together with recent data showing that TIZ blocks 
Influenza virus replication at a post-entry level, resulting in impairment of the 
transport of influenza hemagglutinin to cell surface, justified a human clinical trial in 
uncomplicated influenza in adults and adolescents. The choice of testing NTZ, the 
first of thiazolides, was mainly due to the fact that this molecule has been used in 
clinical trials against a number of other types of infections caused by protozoa, 
anaerobic bacteria and viral infections such as rotavirus and HCV.
 
Six hundred and 
twenty-four adults and adolescents with FLU symptoms were enrolled in the study 
within 48 hours of symptom onset.  257 of the 624 patients (41%) had laboratory 
confirmed influenza infection by RT-PCR or viral culture at baseline. Approximately 
half of the influenza-infected patients enrolled in the US clinical trial were infected 
with influenza A subtype H1N1 (“swine flu”) with approximately 30% being infected 
with influenza B and 20% with influenza A subtype H3N2. Patients were blindly 
divided into three groups: placebo (N=89); NTZ 300mg (N=89); NTZ 600mg 
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(N=79). Patients treated with NTZ 600mg for five days experienced statistically 
significant reduction in time from beginning treatment to alleviation of FLU 
symptoms compared to patients receiving the placebo (95 hours vs. 117 hours, 
P=0.01, fig. 29) (P=0.008).  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29 – Time to alleviation of symptoms following treatment with placebo, 300 or 600 
mg of NTZ in a cohort of FLU-infected patients (A). Median time to alleviation and pvalues 
vs placebo are shown (B). 
 
Time to resolution of symptoms for the low dose group were less than for the 
placebo, but the difference was not statistically significant (P=0.521). Patients in 
the 600 mg NTZ treatment group also experienced statistically significant 
reductions in quantitative viral shedding compared to patients receiving the 
placebo (P=0.0006, fig. 30).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30 – Change over time in viral titer following treatment with placebo, 300 or 600 mg 
of NTZ in a cohort of FLU-infected patients 
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Additional results showed that seroprotection and seroconversion rates (Influenza 
B and H3N2 strains) were higher in both groups of NTZ patients compared to the 
placebo control group (fig. 31).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 31 – Seroprotection and seroconversion rates in patients infected with different 
influenza strains, after treatment with placebo, 300 or 600 mg of NTZ 
 
Notably, no differences in the severity or the frequency of adverse events were 
reported in the NTZ compared to placebo group of patients (tab. 7). These data 
indicate that immunostimulatory effects associated with NTZ in vitro and in vivo are 
translated into significant clinical benefits. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7 – Common adverse events observed in 1% of patients included in the clinical trial 
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3. HIV-1BAL INFECTION 
3.1. Strong antiviral activity of thiazolides against HIV-1BaL infection in 
vitro  
Since thiazolides were shown to be effective in triggering a protective antiviral 
response against a wide variety of viruses, we verified suitability of these 
compounds in the treatment of another viral infection, in particular HIV-1. In this 
regard, thiazolide antiviral activity was investigated in human PBMCs post HIV-1BaL 
infection. p24 viral antigen release from infected cells was significantly reduced 
after TIZ or RM4848 treatment compared to untreated conditions (p-value< 0.01 for 
both compounds). Percentages of HIV-1 infection inhibition were 87.8% and 96.5% 
after TIZ- and RM4848-treatment, respectively (fig. 32). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32 – p24 viral antigen levels in the supernatant of HIV-1BaL infected PBMCs treated 
with TIZ (10 µg/ml) or RM4848 (10 µg/ml) 10 days post-infection (A). Percentage of viral 
replication inhibition following TIZ (10 µg/ml) or RM4848 (10 µg/ml) treatment in HIV-1BaL 
infected PBMCs 10 days post-infection (B). Mean values ± standard errors are shown. 
 
As we observed a stronger effect of RM4848 on viral replication compared to TIZ, 
we decided to further deepen its action and kinetic by adding RM4848 to cell 
cultures at different time-points. In this regard, the experiment was set up as shown 
in Fig. 33. 
 
n
o
 d
ru
g
g
/m
l)

T
IZ
 (
1
0
g
/m
l)

R
M
4
8
4
8
 (
1
0
0
10000
20000
30000
40000
50000
100000
200000
300000
400000
500000
*** p<0.01
*** p<0.01
p
2
4
 (
p
g
/m
l)
g
/m
l)

T
IZ
 (
1
0
g
/m
l)

R
M
4
8
4
8
 (
1
0
0
20
40
60
80
100 87.8%
96.5%
%
 o
f 
H
IV
-1
 i
n
fe
c
ti
o
n
 i
n
h
ib
it
io
n
B A 
Results and Discussion 
  
 
68 
 
 
 
Figure 33 – Schematic representation of the experiment performed to test RM4848 action 
and kinetics.  
 
A reduction of p24 levels was observed in all RM4848 treated-samples compared 
to untreated controls, suggesting that second generation thiazolides exert an 
immunomodulatory effect rather than directly interfering with HIV-1 replicative life 
cycle. However, inhibition of viral replication reaches statistical significance only 
when RM4848 treatment is performed post infection or maintained over time in cell 
culture until 10 days post infection; otherwise it’s effect is progressively weakened 
presumably because of a gradual attenuation of the immunomodulatory properties 
of the compound in all the other conditions (fig. 33). 
  
 
 
Figure 33 – p24 viral antigen levels of HIV-1BaL infected PBMCs treated with RM4848 (10 
µg/ml): pre-infection (blue), during infection (green), post infection (yellow), during all the 
experiment course (red), at different time points. Mean ± standard errors are shown. 
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3.2. Evaluation of thiazolide cytotoxicity in HIV-1-infected cells 
Viability of cells is a crucial factor influencing the quality of HIV-1 replication assay. 
Viability of HIV-1-infected cells was monitored during treatment with thiazolides by 
7-AAD staining, in order to evaluate the percentage of cell death as a result of 
thiazolide cytotoxicity. Results indicated that TIZ or RM4848 exposure did not alter 
the viability of PBMCs at the concentrations assayed at different time-points (fig. 
34). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34 – Percentage of 7-AAD positive (non viable) PBMCs treated with  TIZ (10 µg/ml) 
(A) or RM4848 (10 µg/ml) (B) after 3, 5 or 7 days of incubation, in basal condition or after 
HIV-1BaL infection. Mean values ± standard errors are shown. 
3.3. Modulation of type I IFN pathway after thiazolide treatment 
To determine whether thiazolide treatment could increase type I IFN and ISG 
expression levels also in the in vitro model of HIV-1-infection, we performed a 
Real-time PCR array that screens simultaneously 84 gene involved in type I IFN 
response.  
Results from uninfected cells incubated with TIZ showed an increased expression 
of IFNα1, IFNα2, IFNα4, IFNβ1, and IFN, ISGs (ARL5B, IRF7, MET, OAS2, 
PRKRA, SHB, STAT2, TRAF3), and HLA-C a gene involved in antigen 
presentation (fig. 35A). RM4848 treatment resulted in the upregulation of IFNα2, 
IFNα4, IFNAR1, IFNAR2, IFNβ1, and IFN, ISGs (CAV1, IFI30, IRF5, IRF7, ISG15, 
ISG20, ITIH2, MX2, SHB, STAT2), antigen presentation genes (HLA-C, HLA-
DQA1), and a downstream effector gene involved in this pathway (VEGFA) (fig. 
35B).  
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Figure 35 – mRNA expression of genes involved in type I IFN pathway following TIZ (10 
g/ml) (A) or RM4848 (10 g/ml) (B) treatment in uninfected condition  
 
Results from HIV-1-infected cells incubated with TIZ showed an upregulation of 18 
genes. Data showed an increase in IFNα1, IFNα2, IFNα4, IFNβ1 and in the HLA-C 
gene. Moreover, TIZ moderately upregulated different ISGs (IRF1, IRF2, IRF7, 
MX1, MyD88, OAS2, SHB, TRAF3) and a gene involved in the pathway (CD70). 
Again, RM4848 effect was shown to be stronger than TIZ (fig. 36) in this action. 
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Figure 36 - mRNA expression of genes involved in type I IFN pathway following TIZ (10 
g/ml) (A) or RM4848 (10 g/ml) (B) treatment in HIV-1-infected condition 
3.4. Analysis of anti-HIV-1 human response pathway 
To determine whether the anti-HIV effects of thiazolides result in a specific 
modulation of cellular factors directly involved in HIV-1 life cycle, we used an anti- 
HIV-1 human response pathway array that screens for the expression of different 
genes known to directly interfere with HIV. 
Data showed that thiazolides result in the reinforcement of innate immune 
responses rather than affecting cellular mechanisms used by HIV-1 for replication 
and survival. These data confirmed the hypothesis of an effective immune 
stimulation exerted by these compounds. Notably, RM4848 seems to be endowed 
with a stronger immunomodulatory activity compared to TIZ (fig. 37). 
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Figure 37 – mRNA expression of genes involved in HIV-1 human response pathway 
following TIZ (10 g/ml) (A) or RM4848 (10 g/ml) (B) treatment in HIV-1-infected condition 
3.5. Thiazolides modulate cytokine and chemokine production in HIV-
1 infected PBMCs 
Cytokine and chemokine production by in vitro HIV-infected thiazolide-treated 
PBMCs was measured in supernatants 3 days after HIV-1BaL infection by Multiplex 
Detection Immunoassay. Results showed that IFN and IL2 (Th1-cytokines) 
production was significantly increased in HIV-1 infected cells in the presence of TIZ 
(p-value=0.05) or RM4848 (p-value=0.05). Interestingly, chemokine production 
(MCP-1, MIP1-α, MIP1-β, RANTES), known to be endowed with anti-HIV 
properties, was strongly modulated by thiazolides as well.  
In particular, HIV-infected cells treated with TIZ (fig. 38) or RM4848 (fig. 39) 
showed an increased release of MIP-1α (TIZ: p-value=0.03, RM4848: p-
value=0.05), MIP-1β (TIZ: p-value=0.03, RM4848: p-value=0.05), MCP-1 (TIZ: p-
value=0.05, RM4848: p-value=0.05) and RANTES (TIZ: p-value=0.05, RM4848: p-
value=0.03). 
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Figure 38 – Cytokines and chemokines supernatant concentration of uninfected and HIV-1 
infected cells untreated (white bars) ore treated (grey bars) with TIZ (10 µg/ml)  3 days  post-
infection . Mean values ± standard errors are shown.  
 
Recently, it was suggested that NTZ acts after viral entry and before or during 
reverse transcription step. The increased production of pro-inflammatory cytokines 
and chemokines reported in the in vitro assays, nevertheless indicate that TIZ or 
RM4848 could either obstacle viral entry or reduce the infection process of target 
cells once the virus has replicated. 
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Figure 39 - Cytokines and chemokines supernatant concentration in uninfected and HIV- 
infected cells in presence of RM4848 (10 µg/ml) at day 3 post-infection. Mean and p values 
are shown 
3.6. Interferon-inducible cholesterol-25-hydroxylase (CH25H) broadly 
inhibits viral entry 
Since we previously demonstrated that thiazolide treatment results in IFN and ISG 
upregulation, we thus verified whether pharmacological immunomodulation may 
also affect cholesterol metabolism, and in particular CH25H expression. In this 
regard, we designed custom PCR arrays to analyse a wide range of genes 
involved in intracellular cholesterol trafficking and metabolism. Results obtained in 
uninfected PBMCs confirmed our hypothesis, showing an upregulation of genes 
involved in cholesterol metabolism and efflux (CH25H, NR1H3, RXRα, SREBF1, 
SREBF2) and of different membrane receptors and cholesterol transporters 
(MSR1, ABCA1) in the presence of TIZ (10 µg/ml). RM4848 stimulation showed a 
similar trend with a higher effect compared to TIZ (fig. 40).  
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Figure 40 – Cholesterol metabolism and efflux gene expression following stimulation with 
TIZ (10 µg/ml) (A) or RM4848 (10 µg/ml) (B) in uninfected conditions. 
 
Data obtained on HIV-1-infected TIZ-stimulated PBMCs  confirmed upregulation of 
CH25H, NR1H3, PPAR, SREBF1, and SREBF2 expression, which represent the 
main regulators of cholesterol metabolism and efflux. Moreover, MSR1, LDLR, 
ABCG1 and ABCA1, membrane receptors involved in cholesterol metabolism and 
efflux were also increased by TIZ. RM4848 stimulation resulted in the upregulation 
of CH25H, NR1H2, NR1H3, PPAR, RXRα, RXRβ, SREBF1, SREBF2 and of 
MSR1, LDLR, ABCA1, and ABCG1 as well (fig. 41). 
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Figure 41 - Cholesterol metabolism and efflux gene expression following stimulation with 
TIZ (10 µg/ml) (A) or RM4848 (10 µg/ml) (B) in HIV-1 infected cells. 
 
Results herein presented showed that thiazolides potently induce antiviral 
responses by enhancing type I IFN production and the expression of a wide range 
of genes involved in cholesterol metabolism. Among these, CH25H and 25-HC, a 
natural oxysterol that is produced through a CH25H-mediated enzymatic reaction, 
play an important role in preventing viral spread to target cells. It is well known that 
most natural oxysterols act as ligands for LXR, which has been extensively shown 
to mediate cholesterol efflux throughout the cells. Although we did not quantify 25-
HC levels in the supernatants of HIV-1BaL infected cells, we verified a possible 
correlation between upregulation of genes involved in cholesterol efflux and in vitro 
inhibition of HIV-1 infection. In this context, we stimulated HIV-1BaL infected cells 
with a synthetic agonist of LXR (TO-901317) and assessed viral infectivity by p24 
dosage. Data showed a statistically significant decrease of cell infection by 47% in 
TO-901317-treated samples compared to controls.  
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These results suggest that reduction of viral replication is partially achievable 
through modulation of cholesterol efflux mechanisms (fig. 42). This hypothesis 
should be nevertheless confirmed by further studies. 
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Figure 42 -  p24 viral antigen levels of HIV-1BaL infected PBMCs in presence or absence of 
TO-901317 (1 µM) 10 days post-infection. Mean ± standard errors are shown. 
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The ability of thiazolides to interfere with pathogens that are radically different in 
their structure and in the pathogenic mechanisms of action suggested that these 
compounds are endowed with a potent and non pathogen-specific activity. 
In this regard, we initially investigated the possibility that thiazolides effects could 
be associated with the elicitation of both innate and acquired immunity in influenza 
virus model. Our results indicate that first and second generation thiazolides were 
able to upregulate gene expression of multiple components of the TLR- and type I 
IFN-signal transduction pathways, of multiple chemokines and cytokines, as well as 
the production of IFNα by pDC, and that of IL2 and IFN by CD4+ T lymphocytes.  
The fact that NTZ had been extensively used in clinical setting, and recent data 
indicating that TIZ inhibits viral replication of several strains of influenza A H1N1, 
H3N2 and influenza B viruses at a post-entry level [37], prompted us to further 
verify the possible effect of NTZ in the in vivo condition. Results obtained in a 
double-blinded, placebo-controlled clinical trial in patients with Influenza infection 
showed a clear effect of NTZ in reducing the severity of FLU symptoms and 
viremia, and in increasing seroprotection and seroconversion rates. These data 
indicate that the ability of NTZ/TIZ to upregulate innate immune responses in vitro 
are reflected in a clear clinical advantage. Because of the study design we could 
not perform ex-vivo analyses on cells of patients enrolled in the trial. It is 
nevertheless reasonable to believe that the immunomodulatory effect of NTZ we 
observed in vitro are responsible for the activation of a multifaceted immune 
response in vivo, resulting in the observed clinical benefit of the drug.  
Moreover, immunomodulatory effects of thiazolides were stronger in FLU-
stimulated cells compared to unstimulated control, suggesting that thiazolides 
result in the reinforcement of immune responses. This remarkable selectivity 
seems to justify the lack of adverse clinical side effects that characterize the clinical 
use of  NTZ. Indeed, data obtained both in clinical trials as well as data presented 
here, did not evidence any drug-related toxicity. This feature clearly sets apart NTZ 
in respect to other immune based therapies (e.g. IFN, IL-2, IL-12, etc) that are 
associated with common and severe side effects resulting from a generalized and 
extensive immune activation (i.e. cytokine storm).  
Considering the overall results obtained in influenza virus model, we further 
reasoned on the possible role of thiazolides in elicitation of effective innate immune 
responses against HIV-1. In this context, induction of robust innate immune 
responses is correlated with a reduced susceptibility to HIV-1 infection in vivo a 
condition distinctive  of subjects who despite repeated exposure to the virus do not 
seroconvert (HIV exposed seronegative individuals, HESN). Indeed, recent data 
showed that in vitro HIV replication is significantly reduced in PBMCs of HESN and 
that this effect is secondary to the elicitation of a prompter and more robust innate 
immune response [179].  
Thiazolide treatment resulted in the reduction of in vitro HIV-1 replication in cells 
isolated from healthy individuals, conferring to these cells an “HESN-like” status. 
As our results demonstrated that thiazolides induce a modulation of the whole 
innate immune compartment we could reasonably speculated that this effect is 
responsible for HIV-1-infection reduction. Actually, in the presence of both 
thiazolides cytokine and chemokine secretion well as that of type I IFN genes  and 
interferon-stimulated genes (ISGs) were significantly augmented in HIV-1BaL 
Conclusions 
  
 
80 
 
infected human PBMCs.  Among ISGs, the increased expression of OAS1, OAS2, 
PRKRA, MX1 and MX2 is particularly intriguing as their activity is strongly 
associated with the induction of antiviral resistance mechanisms. Furthermore, 
experimental observations support the hypothesis that IFN effectors work in 
cooperation to achieve a fully functional antiviral state. Combination of different 
ISGs expressed together results in a greater magnitude of antiviral activity than 
either gene alone. Thus, the greater efficacy of RM4848 in reducing HIV-1-infection 
could be correlated to a broadly range of ISGs upregulated compared to TIZ.  
To better unravel the mechanism of action exerted by thiazolides and given the 
high number of ISGs induced by these drugs, we finally focused our attention on 
CH25H, an oxysterols producing enzyme. CH25H inhibits growth of a wide range 
of enveloped viruses by producing 25HC, which in turn impairs viral entry at the 
virus-cell fusion step by inducing cellular membrane changes. Interestingly, our 
results confirmed the involvement of CH25H in thiazolide-mediated effects. This 
fascinating perspective led us to deepen the intriguing connection between 
modulation of cholesterol metabolism and reduction of viral infection mediated by 
thiazolides. Consequently, we found an increase of cholesterol metabolism (LXR, 
PPAR) and influx or efflux (ABCA1, ABCG1, MSRI, LDLR) genes. RM4848 results 
in a stronger effects compared to TIZ. Further, we reported that cholesterol efflux 
induction by an LXR agonist (TO-901317) is associated with a reduction of HIV-1-
infectivity.  
Results herein presented allow us to speculate that mechanisms of antiviral activity 
of thiazolides are entirely new, and are mediated by a robust activation of innate 
immune system and a modulation of genes involved in cholesterol efflux and 
metabolism. However, to date, an explanation for the mechanism of action of 
thiazolides in various disease conditions remains theoretical but clearly deserving 
further studies. Given the complexity of IFN regulation pathway, major information 
could arise from animal studies in which the immune system can be manipulated. 
Additional disease models and future clinical trials will be needed to elucidate the 
role of thiazolides in immune-system regulation. In conclusion, thiazolides could be 
considered by the medical community for the design of novel preventive and 
therapeutical approaches against HIV-1 infection. 
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